

Manuscript Number: CARBPOL-D-17-02717R1

Title: Freeze dried chitosan acetate dressings with glycosaminoglycans and tranexamic acid

Article Type: Research Paper

Keywords: chitosan; glycosaminoglycans; tranexamic acid; blood clotting; wound healing

Corresponding Author: Professor Giuseppina Sandri, PhD

Corresponding Author's Institution: University of Pavia

First Author: Francesca Saporito

Order of Authors: Francesca Saporito; Giuseppina Sandri, PhD; Silvia Rossi; Maria Cristina Bonferoni; Federica Riva; Lorenzo Malavasi; Carla Caramella; Franca Ferrari

Abstract: Bleeding control plays an important role to increase survival in the early phase after a traumatic event.

The aim of the present work was the development of hemostatic sponge-like dressings based on chitosan, in association with glycosaminoglycans (GAG as chondroitin sulfate or hyaluronic acid) and the improvement of their hemostatic performance by loading tranexamic acid (TA). The dressings were prepared by lyophilization and were characterized for mechanical, hydration, bioadhesion properties and morphology. Moreover FTIR analysis was performed to understand the interactions between the different polyelectrolytes present in the dressing. Clotting was investigated in vitro by using rat whole blood. Moreover in vitro biocompatibility and proliferation were evaluated towards fibroblasts. Ex vivo proliferation properties were assessed by using human skin.

All the dressings were characterized by mechanical, hydration and bioadhesion properties suitable to be applied on bleeding wounds and to absorb bleeding or wound exudate, avoiding tissue dehydration. TA release was fast and TA and chitosan showed a synergic effect to speed up clotting. The dressings were biocompatible and able to sustain cell proliferation in vitro and ex vivo in human epidermis. In conclusion, sponge-like dressings based on chitosan and GAG and loaded with TA are an effective tool to enhance hemostasis and healing in bleeding wounds.

Dear Editor,

please consider the revised version of the paper previously entitled "Improvement of hemostatic dressings based on chitosan and glycosaminoglycans by tranexamic acid" and now entitled "Freeze dried chitosan acetate dressings with glycosaminoglycans and tranexamic acid" as suggested. The manuscript was carefully revised considering all the points raised by the reviewers.

The aim of paper submitted is the development of hemostatic sponge-like dressings based on chitosan, in association with glycosaminoglycans (GAG as chondroitin sulfate or hyaluronic acid) and the improvement of their hemostatic performance by loading tranexamic acid (TA).

The significance of the research considers two fundamental aspects: the first one is related to the development of sponge-like dressings with optimal technological properties (mechanical, hydration and bioadhesive), while the second one is related to the possibility to speed up clotting and to enhance wound healing by cell proliferation.

The characterization of these systems involved a multidisciplinary approach considering integrated techniques of pharmaceutical technology, and in vitro/ex vivo models to understand clotting, biocompatibility and proliferation properties (enhancement of in vitro and ex vivo proliferation on fibroblast and human skin biopsy, respectively).

A deeper characterization of the physico-chemical properties of the developed dressings was performed: FT-IR, SEM analysis and acetic acid titration was added in the paper and XRPD analysis was performed but not included into the paper. These evaluations, in line with the requests of the reviewers, allowed to characterize the systems from solid state point of view. These further characterizations completed the comprehension of the behaviour of the developed dressings upon hydration and of the bioadhesion phenomenon.

Thanks in advance for your consideration,

Best regards

Giuseppina Sandri

Highlights

Chitosan and glycosaminoglycan dressings are characterized by mechanical, hydration and bioadhesive properties suitable to be applied on bleeding wounds.

Chitosan and glycosaminoglycan interaction was studied by FTIR and dressing morphology was characterized by SEM.

Chitosan and tranexamic acid have a synergic effect in clot formation.

The authors wish to thank the reviewers for their fruitful comments to improve the quality of the paper. All the changes in the manuscripts were in red, as requested.


Editor

1. Following the editor's suggestion the title was changed in "Freeze dried chitosan acetate dressings with glycosaminoglycans and traxenamic acid"
2. The reference suggested Bartley et al., 2013 was added and the following comment was added in the text: "Bartley (2013) suggested that the association of chitosan with TA should improve hemostatic control and should lead to improved clinical outcomes in internal surgical wounds."
3. The rationale of the work was better stated in the introduction part and the discussion of the results was improved.

Acetic acid titration was performed on dressings and the comment of results was added in the text as follows "Moreover lyophilization caused acetic acid evaporation. In particular, acetic acid was added, to form chitosan acetate, in excess: 350  $\mu\text{mol}$  of acetic acid were added to 110  $\mu\text{mol}$  of chitosan per each dressing prepared, starting from chitosan at 1% w/w. The titration of acetic acid residues after lyophilization revealed that there was a residues of  $5\pm 1$   $\mu\text{mol}$  per each systems independently of the addition of HA or CS. This is conceivably due to the almost total removal of acetic acid in excess (not involved in chitosan salification)."

Paracrystallinity of the dressings was checked by means of XRPD analysis. XRPD measurements were performed using a D5005 Bruker diffractometer (Karlsruhe, Germany) (CuK $\alpha$  radiation,  $\lambda(\text{K}\alpha 1) = 1.54056$   $\text{\AA}$ ; voltage of 40 kV and current of 40 mA) equipped with a  $\theta$ - $\theta$  vertical goniometer, Ni filter, monochromator and scintillator counter. The patterns were recorded at room temperature in step scan mode (step size: 0.020 $^\circ$ , counting time: 3 s per step) in the  $5 < 2\theta < 35$  angular range.

The patters did not present any peaks to suggest the lacking of paracrillanity. The data have not be included in the text but hereafter as example you can see the CH 1 HA patter.



The bioadhesion paragraph in the results and discussion part was completely rewritten, also following the suggestions of reviewer #1, as follows. Figure 3 reports maximum force of bioadhesion (mN) all the dressings prepared: a) without lyoprotectant, b) with glycerol and c) with mannitol as lyoprotectans.

As for dressings without lyoprotectants (Fig. 3 a), chitosan concentration influenced bioadhesive behavior: CH 2 sponge-like dressing (containing higher chitosan amount) did not show bioadhesive

propensity ( $F_{max}$  measured without biological substrate was not significantly different with respect to the value in presence of biological substrate – egg shell membrane) while CH 1 dressing (containing chitosan at lower amount) was characterized by good bioadhesive properties. Such a behavior is probably due to a different degree of entanglement between chitosan polymeric chains. In particular, the lowest chitosan concentration the lowest the entanglement and the highest the capability to form a bioadhesive joint with the biological substrate (Rossi, Ferrari, Bonferoni, Caramella, 2001).

Since zeta potential analysis confirmed that there was not a complete neutralization of CH with GAGs and both CH-HA and CH-CS had positive zeta potentials, the presence of GAG in dressings significantly enhanced the bioadhesive properties. The interaction between chitosan and GAG probably assisted bioadhesive joint consolidation, considering a higher concentration of carboxylic and OH residues in these systems with respect to that of CH 1. The highest presence of these groups able to form hydrogen bonds could consolidate bioadhesive properties of chitosan, that are mainly due to its positive charge density. Chitosan and GAG physical mixtures (CH-HApm, and CH-CSpm) did not show bioadhesive properties: these are easily inferred by the negligible solubility properties of chitosan at pH 7.2 phosphate buffer (hydration medium chosen to mimic wound bed exudate). Moreover CS or HA, as powders, were also considered and they showed a lack of bioadhesion in those conditions: this was probably due to slower hydration of HA during the test with respect to the lyophilized dressings and to the poor bioadhesive strength of CS mainly caused by its low molecular weight. In presence of lyoprotectants, both mannitol and glycerol (Fig. 3 b and c, respectively), the bioadhesive properties were less pronounced and were significant only for HA and CS dressings with mannitol. The presence of lyoprotectants, especially of mannitol, that increased system stiffness and probably decreased polymer chain mobility, could impair polymer capability to interact with the biological substrate.

Also bioadhesion is a crucial characteristic that should favor an intimate and prolonged contact between wound dressings and lesion, favoring blood absorption and avoiding formulation detachment to increase the hemostatic potential.

Moreover zeta potential evaluation and SEM analysis to study system morphology were added.

#### Reviewer #1

L111/Table 1: According to reviewer's suggestions, average molecular mass of both CS and HA was included in the materials section as follows: "The following materials were used: Chitosan (CH) low MW 251000 Da, deacetylation degree 98%, maximum charge density: number of positively charged functional group per repeated unit: 0.98 (ChitoClear, Siiiglufjordur-Iceland); Hyaluronic Acid (HA) low MW 212000 Da; maximum charge density: number of negatively charged functional group per repeated unit: 0.5 (Bioiberica, Barenz, Italy); Chondroitin sodium sulfate bovine 100 EP (CS) low MW 14000 Da, mixture of A (chondroitin 4 sulfate) and C (chondroitin 6 sulfate); maximum charge density: number of negatively charged functional group per repeated unit: 1 (Bioiberica, Barenz, Italy); Trans-4 (amino-methyl) cyclohexanecarboxylic acid (Sigma Aldrich, Milan-Italy); Glycerol (g) 30° Be (Carlo Erba, Italy); D-Mannitol (Fluka, France)"

The charge density (number of negatively charged functional grouped per repeated unit) and the charge molar ratio between the two polyelectrolytes were also added for both CS and HA in the results and discussion section. "charge density (positive) is 0.006 mole/g for chitosan, 0.0013 mole/g for HA (negative) and 0.002 mole/g for CS (negative) with a clear excess of positive charges, in both cases. The charge molar ratio of CH – HA was 4.6 while that of CH – CS was 3."

The rationale about the employment of acetate rather than hydrochloride was assessed in the experimental part 2.2.1. Sponge-like dressing preparation as follows: . Acetate was used as counterion to obtain chitosan salification in mild pH conditions and it was preferred to hydrochloric acid because chitosan fragmentation could occur in HCl environment also at low molarity (Sabnis, Block, 2000).

L117/L118: According to reviewer's suggestions, in the experimental part the paragraph "2.2.1. Sponge-like dressing preparation" was rewritten including acetic acid concentration details and the visual observation of the systems prepared as follows "CH was hydrated in acetic acid 1% w/w (glacial acetic acid, Sigma Aldrich, Italy) under gentle stirring at room temperature. Acetate was used as counterion to obtain chitosan salification in mild pH conditions and it was preferred to hydrochloric acid because chitosan fragmentation could occur in HCl environment also at low molarity (Sabnis, Block, 2000).

HA and CS were hydrated in distilled water under gentle stirring at room temperature. The two polymeric solutions were mixed 1:1 weight ratio to obtain polymeric mixtures. Systems containing CH alone were mixed

1:1 weight ratio with bidistilled water. Final acetic acid concentration in the polymeric systems was 0.5% w/w. CH 1 - HA and CH 1 - CS mixtures and CH 1, were subjected to zeta potential evaluation. Measurements were carried out at 25°C by means of a Malvern Zetasizer Nano ZS90 (Malvern Ltd., UK). HA and CS solutions, prepared in the same concentrations used for CH 1 - HA and CH 1 - CS mixtures but without CH were also tested.

In two series of preparations of CH 1 - HA and CH 1 - CS mixtures and CH 1, glycerol or mannitol were added as lyoprotectants. Polymeric solutions appeared transparent without visible precipitate. As for TA loaded systems drug was added to the polymeric mixture at 0.75% w/w. Two ml of each mixture were poured into each well of 12-well plate (well area 3.8 cm<sup>2</sup>). In the TA loaded systems the drug was 4 mg/cm<sup>2</sup>. All the polymeric solutions were frozen at -40°C overnight and freeze-dried (Heto 15, Analitica De Mori, I) for 24 h. All the dressings prepared were 5 mm thick (sd ± 0.52).

CH, HA and CS were at 5 mg/cm<sup>2</sup> concentration in CH 1 dressings; CH was at 10 mg/cm<sup>2</sup> concentration in CH 2 dressings, glycerol was at 1.3 mg/cm<sup>2</sup> while mannitol was at 10.5 mg/cm<sup>2</sup>.

Dressings were re-solubilized in distilled water to check the eventual residues of acetic acid (2 g of distilled water per each dressing). pH of each sample was measured by means of a pHmeter (pH 210 Microprocessor, Hanna Instruments, Italy) and the acetic acid excess was titrated by means of acid-base titration by using phenolphthalein as indicator and NaOH 0.1 M (Carlo Erba, Italy).

L214: in the experimental part paragraph “2.2.2.8. In vitro biocompatibility and proliferation” requested details about sample preparation were added as follows “ After 24 h cells were washed with saline solution and placed in contact with 200 µl of CH, CH-CS and CH-HA polymeric mixtures (prepared as reported in the section 2.2.1.) at 1:20 (CH, CS or HA at 500 µg/ml, solubilized in cell growth medium) and 1:50 (CH, CS or HA at 200 µg/ml, solubilized in cell growth medium) dilutions with growth medium (GM).

L263-268: According to reviewer’s suggestions, the section was completely rewritten: a discussion about the PECs formation was added including also references about the topic and the concept of guest-host was discussed, as follows: “The increase of chitosan amounts in the dressings increased the mechanical resistance of the formulations: stiffness was significantly greater when lyoprotectants (glycerol or mannitol) were included in the formulations. The presence of HA in the dressings caused a significantly increase in the mechanical resistance and HA based formulation with mannitol, as lyoprotectant, was characterized by the higher Fmax value to indicate a more rigid structure. This behavior could probably due to the high molecular weight of HA, with respect to CS, that could dramatically strengthen the tridimensional network of the system. It is conceivable that HA interacted with chitosan during the preparation procedure, forming a polyelectrolyte complex (PEC) between chitosan and hyaluronate. Since both CH and HA have similar molecular weight the interaction between the two polymers should be able to form a highly crosslinked structure.

On the contrary, the presence of CS in the formulation did not significantly change the stiffness of the dressings. This is probably due to the resulting PEC formed by an interaction between CS and CH: CS is characterized by a molecular weight 18 folds lower than that of CH, moreover sulfate groups of CS (more acid with respect to carboxylic group) could cause a coiled structure less prone to polymer chain entanglements. This probably rendered the dressing structure less stiff.

As reported in literature, structure and stability of PECs strongly depend on different parameters such as concentrations of each polyelectrolyte, charge molar ratio, charge density, molar masses and chain flexibility but depend also on extrinsic parameters as pH, ionic strength and/or temperature (Kabanov, 2005; Feng, Leduc, and Pelton, 2008; Le Cerf, D., Pepin, A. S., Niang, P.M., Cristea et al., 2014).

According to all these parameters, mixing oppositely charged polyelectrolytes could give two types of PECs dependently of charge stoichiometry: soluble PECs, leading to stable and transparent solutions, and insoluble PECs, with or without precipitation. The soluble PECs are obtained with an excess of anionic or cationic charges (Feng, Leduc, and Pelton, 2008; Kabanov and Zezin, 1984; Schatz, Domard, Viton, Pichot, et al., 2004) and this was the case of CH-HA and CH-CS. In fact, charge density (positive) is 0.006 mole/g for chitosan, 0.0013 mole/g for HA (negative) and 0.002 mole/g for CS (negative) with a clear excess of positive charges, in both cases. The charge molar ratio of CH – HA was 4.6 while that of CH – CS was 3. Moreover Denunziere, Ferrier, and Domard (1996) reported interaction between CS and CH was independent of CS sulfate substitution on 4 or 6 carbons.

Zeta potential evaluation was also added in the text (experimental part and Results and discussion part ) as follows: This was confirmed by zeta potential evaluation. CH 1 had a positive zeta potential of 53.2±1.9 (mean value±sd; n=3) while HA and CS as solutions showed negative zeta potentials of -27.9±0.9 and -16.8±1.2, respectively (mean value±sd; n=3). CH 1 – HA and CH 1 – CS were characterized by positive zeta potentials of 39.3±0.3 and 25.3±0.8, respectively (mean value±sd; n=3). These results supported that the

interaction between CH and GAGs did not cause a neutralization of the two polyelectrolytes mixed (CH and HA or CS) and an excess of positive charges was present.

Acetic acid titration was performed and the results were commented as follows: “Moreover lyophilization caused acetic acid evaporation. In particular, acetic acid was added, to form chitosan acetate, in excess: 350  $\mu\text{mol}$  of acetic acid were added to 110  $\mu\text{mol}$  of chitosan per each dressing prepared, starting from chitosan at 1% w/w. The titration of acetic acid residues after lyophilization revealed that there was a residues of  $5\pm 1$   $\mu\text{mol}$  per each systems independently of the addition of HA or CS. This is conceivably due to the almost total removal of acetic acid in excess (not involved in chitosan salification).<sup>2</sup>

Morphology was also assessed by means of SEM and the results were commented as follows: To understand if the system tridimensional networks could affect hydration and bioadhesion properties, morphology was assessed.

Figure 4 reports SEM images of transversal sections of CH 1, CH 1- HA and CH 1 – CS unloaded dressings and TA loaded dressings without lyoprotectants, and CH 1, CH 1- HA and CH 1 – CS dressings with glycerol and with mannitol.

CH 1 dressing showed a beehive structure with polyhedric cavities interconnected by pores having oval or round shapes. The cavities had dimensions of about 500  $\mu\text{m}$  while the pores ranged from 50 to 200  $\mu\text{m}$ . The presence of GAG did not change the system morphology while it markedly decreased the cavity dimensions that were around 200-300  $\mu\text{m}$  and furthermore the pore diameters that were of about 50  $\mu\text{m}$ . This difference in system porosity conceivably contributed to their hydration behavior. The TA loading did not modify the structure of the dressings.

The presence of glycerol as lyoprotectant did not substantially change dressing structure while the presence of mannitol caused a partially loss of polyhedric cavities and the structure resembled much more randomly organized sheets without marked modifications of the porosity. This modification could be responsible to the system behavior upon hydration and bioadhesion.

Since lyoprotectants did not markedly improve the technological properties of the dressings and considering mechanical, hydration and bioadhesive properties, lyoprotectant free systems prepared using chitosan at 1% w/w were considered for the further characterizations.

L289-301: the protonation of CH after lyophilization was assessed in the dressings by means of FTIR analysis and also to study interpolymer interactions. The results of FTIR analysis were commented as follows:

Figure 5 reports the FT-IR spectra of CH 1, CH 1 – HA and CH 1 – CS HA and CH+CS dressings and of CH powder (in the inset) as comparison.




Figure 5: FT-IR spectra of CH 1, CH 1 – HA and CH 1 – CS HA and CH+CS dressings. In the inset the FTIR spectrum of CH powder (free CH) is reported as comparison.

The three spectra shared many common features both in the number and position of the peaks and seemed to be dominated by the FT-IR pattern of CH (free CH as powder), where the region around 1630 and 1540  $\text{cm}^{-1}$  is typical of the amide I and amide II stretching and bending modes (Radhakumary, Antony, Sreenivasan, 2011; Jayakumar, Prabhakaran, Nair, Tamura, 2010). Interestingly, the position of these peaks shifted to lower frequency with respect to free CH (i.e. not interacting with acetate ions) shown Figure 1 inset. In particular, the  $\text{-C=O}$  stretching of the amide I in free CH moved from 1652 to 1634  $\text{cm}^{-1}$  when it interacted with acetate ions and it remained in the same position even in the CH 1 - HA and CH 1 - CS systems. Moreover, a new peak around 1404  $\text{cm}^{-1}$  (correlated to the  $\text{-C-H-}$  bending) appeared in the spectra of CH 1 dressing with respect to free CH and was found also in the spectra of CH 1 - HA and CH 1 - CS. The two mentioned spectral features have been correlated to charge-charge neutralization (salification) which most probably occurred between CH and acetate ions and dominated the spectra of all the three systems shown in Figure 1 (Shanti Krishna, Radhakumary, Sreenivasan, 2015).

This suggests that, in presence of acetate ions, the charge-charge interaction, involving chitosan amino groups, was preferentially between CH and acetate and therefore the further addition of HA and CS mostly interact with chitosan through less strong bonding such as polar interactions. Such results are in agreement with zeta potential values determined.

Also Zeta potential and acetic acid titration allowed to understand the protonation of chitosan after lyophilization and the interactions between CH and GAG to interpret the hydration results. The rational of hydration properties at pH 7.2 was better evidenced also in the results part (to mimic wound exudates).

Moreover the impact of cryoprotectant on dressings was added as follows:

Glycerol did not markedly change the hydration properties of CH and CH in association with GAG. On the contrary, mannitol substantially decreased the hydration capacity of the systems: this could be related to stiff structure of the dressings, which could slow down and impair liquid penetration into the dressings.

Figure 3: in the experimental part "blank" was explained as follows: Blank measurements were performed by using a filter paper disc wetted with 100  $\mu\text{l}$  of isotonic saline solution (NaCl 0.9% w/v) instead of biological substrate: this allowed to evaluate cohesive properties of the sample.

L350: the bioadhesion section was rewritten and also the experimental part was experiment was better evidenced that biological substrate egg-shell membrane used to mimic wound bed.

L360-361: the suggested samples as comparison were prepared and tested and the Result and discussion section was updated :

Figure 3 reports maximum force of bioadhesion (mN) all the dressings prepared: a) without lyoprotectant, b) with glycerol and c) with mannitol as lyoprotectants.

As for dressings without lyoprotectants (Fig. 3 a), chitosan concentration influenced bioadhesive behavior: CH 2 sponge-like dressing (containing higher chitosan amount) did not show bioadhesive propensity ( $F_{\text{max}}$  measured without biological substrate was not significantly different with respect to the value in presence of biological substrate – egg shell membrane) while CH 1 dressing (containing chitosan at lower amount) was characterized by good bioadhesive properties. Such a behavior is probably due to a different degree of entanglement between chitosan polymeric chains. In particular, the lowest chitosan concentration the lowest the entanglement and the highest the capability to form a bioadhesive joint with the biological substrate (Rossi, Ferrari, Bonferoni, Caramella, 2001).

Since zeta potential analysis confirmed that there was not a complete neutralization of CH with GAGs and both CH-HA and CH-CS had positive zeta potentials, the presence of GAG in dressings significantly enhanced the bioadhesive properties. The interaction between chitosan and GAG probably assisted bioadhesive joint consolidation, considering a higher concentration of carboxylic and OH residues in these systems with respect to that of CH 1. The highest presence of these groups able to form hydrogen bonds could consolidate bioadhesive properties of chitosan, that are mainly due to its positive charge density. Chitosan and GAG physical mixtures (CH-HA<sub>pm</sub>, and CH-CS<sub>pm</sub>) did not show bioadhesive properties: these are easily inferred by the negligible solubility properties of chitosan at pH 7.2 phosphate buffer (hydration medium chosen to mimic wound bed exudate). Moreover CS or HA, as powders, were also considered and they showed a lack of bioadhesion in those conditions: this was probably due to slower hydration of HA during the test with respect to the lyophilized dressings and to the poor bioadhesive strenght of CS mainly caused by its low molecular weight. In presence of lyoprotectants, both mannitol and glycerol (Fig. 3 b and c, respectively), the bioadhesive properties were less pronounced and were significant only for HA and CS dressings with mannitol. The presence of lyoprotectants, especially of mannitol, that increased system



stiffness and probably decreased polymer chain mobility, could impair polymer capability to interact with the biological substrate.

Also bioadhesion is a crucial characteristic that should favor an intimate and prolonged contact between wound dressings and lesion, favoring blood absorption and avoiding formulation detachment to increase the hemostatic potential.

L445: according to reviewer's comment procoagulant activity of CS and HA were considered in the paragraph and references were added to support these findings.

The paragraph was rewritten as follows:

Figure 7 shows % hemoglobin absorbance profiles as function of time evaluated for a) unloaded dressings and b) TA loaded formulations.

A higher degree of hemoglobin absorbance indicates a slower clot formation rate.

Whole blood clotting formation was relatively slow and the hemoglobin absorbance reached the minimum level after about 420 s. A faster clot formation occurred in presence of all the dressings and 30 s immediately after the contact between blood and formulations the % of free hemoglobin was around 20-50%. The minimum level of hemoglobin absorbance was reached after about 300 s. Chitosan capability to bind and aggregate platelets causing agglutination of erythrocytes and activation of hemostasis was predominant in all the formulation considered also in presence of GAG.

TA is a synthetic analogue of lysine and its antifibrinolytic activity is related to reversible bindings with four to five lysine receptor sites on plasminogen or plasmin: this prevents plasmin from binding to and degrading fibrin and preserves clot structure. TA showed a synergic activity with chitosan in enhancing clot formation: all the formulations reached the minimum in hemoglobin absorbance in about 180 s, presenting a better clotting performance with respect to unloaded dressings. TA CH 1 dressing allowed to maintain a % of hemoglobin at 420 s not significantly different from initial value, while CH 1 dressing determined a significant increase in % of hemoglobin comparing the initial value with respect to the final one (at 420 s). TA CH1 -HA and TA CH1- CS dressings proved to maintain clot integrity stable from the beginning up to 420 s, while the same compositions unloaded showed a partial clot modification at 90 s with a sharp increase in % of hemoglobin.

The presence of GAG slightly decreased the procoagulant activity of the dressings. In fact, HA and CS are reported in literature as anticoagulant materials. Fragments of HA having a molecular weight lower than 500 kDa, as it is the case, cause clot structure susceptible to mechanical deformations and softening (Komorowicz, Balazs, Varga, Szabo, et al., 2016). CS is a sulfated glycosaminoglycan with heparin-like activity (Pandolfi, M., Hedner, U., 1984). On this basis, the procoagulant activity of the systems seems exclusively due to chitosan and its synergic effect with TA.

L520: according to reviewer's comment the experimental procedure of in vitro biocompatibility and proliferation was better explained as follows:

"After 24 h cells were washed with saline solution and placed in contact with 200  $\mu$ l of CH, CH-CS and CH-HA polymeric mixtures (prepared as reported in the section 2.2.1.) at 1:20 (CH, CS or HA at 500  $\mu$ g/ml, solubilized in cell growth medium) and 1:50 dilution with growth medium (GM) (CH, CS or HA at 200  $\mu$ g/ml). After dilution, all the samples were transparent without visible precipitate."

Moreover in the paragraph "2.2.1. Sponge-like dressing preparation the details about the appearance of the samples was added as follows: "Polymeric solutions appeared transparent without visible precipitate."

The section was rewritten as follows:

Figure 8 reports % biocompatibility (a) and % of proliferation (b) of all unloaded or TA loaded dressings (polymeric mixtures used to prepare dressings) towards fibroblasts (NHDF) for 3 and 24 h of contact time, respectively, and the amounts of proliferating nuclei/area (c) (positively stained for BrdU) counted for all the unloaded and TA loaded dressings.

Independently of the concentrations considered, all the dressings were characterized by good biocompatibility properties towards fibroblasts also in presence of TA and the cell availability was not significantly different from those obtained with growth medium (GM, standard growth conditions).

Similarly, after 24 h the lower dressing concentrations determined the higher proliferation properties that becomes more evident in presence of tranexamic acid.

These results put in evidence that the presence of the hemostatic drug, TA, did not interfere with cell growth in the experimental conditions considered. Similar results were observed by Cholewinski et al. (2009): carotid artery derived cells maintained their morphology with toxic reaction in presence of TA.

Ex vivo skin cell proliferation (GM) was maximum in the first 24 h and decreased after 72 h and 7 days, except for CS based system that had constant activity (Figure 8 (c)). Unloaded dressings were able to sustain cell proliferation up to 7 days demonstrating a capability to enhance cell proliferation after tissue damage. TA loaded dressings were characterized by the same proliferating properties as unloaded one,

considering CH 1 and CH1 - HA dressings. As for CH1 - CS dressing the presence of TA significantly increased the system proliferation properties after 24 h and 7 days and allowed to obtain the better performance, with a prolonged effect up to one week. This probably was caused by the synergic effect of TA and CS on cell growth: CS was reported as able to enhance fibroblasts and endothelial cells proliferation (Sandri, Bonferoni, Rossi, Ferrari et al., 2015) while TA could stabilize fibrin clot without impairment of cell growth and proliferation (Cholewinski, Dietrich, Flanagan, Schmitz-Rode et al., 2009). At this purpose fibrin clot was conceivably formed just after skin biopsies and it could retain growth factors released by platelets during normal physiological process, on this perspective TA, as fibrinolytic drug, could preserve the clot integrity assisting cell proliferation (Wolberg and Campbell, 2008).

Figure 7: According to the reviewer's comment the figure was deleted

L607-608: the conclusions paragraph was rewritten as follows:

Sponge-like dressings based on chitosan and chondroitin sulfate or hyaluronic acid were prepared by lyophilization and loaded with tranexamic acid. The presence of GAG conceivably caused the occurrence of either chitosan and hyaluronic acid or chitosan and chondroitin sulfate interactions. The presence of glycosaminoglycans decreased hydration properties of the systems in a buffer simulating wound exudate – pH 7.2) and this was primarily due to dressing morphology. Chitosan based dressings had a beehive structure with polyhedric cavities of about 500  $\mu\text{m}$ , interconnected by pores having oval or round shapes (50 to 200  $\mu\text{m}$ ) while dressings based on chitosan in association with GAG markedly decreased the cavity dimensions (200-300  $\mu\text{m}$ ) and with smaller pore diameters (about 50)  $\mu\text{m}$ . Liquid absorption is a key point in dressings to ensure hemostasis, to control wound bed hydration enhancing granulation phase and healing. The presence of GAG in dressings significantly enhanced dressing bioadhesive properties considering as biological substrate egg-shell membrane to mimic wound bed. The association of chitosan with GAG allowed the consolidation of bioadhesive joint probably via hydrogen bonds that strengthen chitosan bioadhesion behavior, mainly due to charge-charge interaction between chitosan and the biological substrate. This is a functional property since bioadhesion is fundamental to favor an intimate and prolonged contact between wound dressings and lesion, avoiding formulation detachment and increasing hemostatic potential. TA release was fast to allow procoagulant function as quickly as possible and moreover to sustain hemostatic activity for prolonged time, to stabilize clot, moreover TA presented a synergic effect with chitosan to speed up clotting formation.

In vitro and ex vivo evaluations on fibroblasts and human skin, respectively, evidenced that the developed dressings enhanced cell proliferation.

Bartley (2013) suggested that the association of chitosan with TA should improve hemostatic control and should lead to improved clinical outcomes in internal surgical wounds. In this paper, sponge-like dressings based on chitosan and GAG and loaded with TA demonstrated to combine both hemostasis and proliferation properties and it seemed promising in control bleeding and healing in wounds as well as in abdominal surgery.

Reviewer #2

- 1) Hydration properties paragraph was completely reorganized as follows:

Figure 2 reports buffer (pH 7.2 phosphate buffer, to mimic wound exudates) taken up a function of time for all the dressings prepared: a) without lyoprotectant, b) with glycerol and c) with mannitol as lyoprotectants.

Considering all the compositions with and without lyoprotectants, chitosan based dressings were characterized by higher buffer taken up vs time profile with respect to those of chitosan and GAG systems; moreover chitosan dressings based on higher CH amounts, showed higher hydration profile even not significantly different from hydration capability of dressing based on lower CH amounts. Dressings based on chitosan and GAG were characterized by significantly lower hydration profiles, independently of both the presence and type of lyoprotectants. All the systems showed a high hydration capacity in the first hour: it is conceivable that chitosan was likely to create a lower pH environment at the dressing/liquid interface and this caused a high liquid absorption probably due chitosan gelation. Subsequently, chitosan poor solubility at neutral pH (pKa 6.5) prevailed over its buffering properties and liquid absorption stopped. The presence of GAG further decreased system hydration probably due to the interpolymer interaction between chitosan and hyaluronic acid or chondroitin sulfate.

Glycerol did not markedly change the hydration properties of CH and CH in association with GAG. On the contrary, mannitol substantially decreased the hydration capacity of the systems: this could

be related to stiff structure of the dressings, which could slow down and impair liquid penetration into the dressings.

Hydration behavior is a crucial point in dressings to ensure hemostasis, to absorb wound exudate and to avoid wound bed dehydration, enhancing granulation phase and healing.

Moreover SEM analysis were performed and hydration was correlated also with system structure, as follows "To understand if the system tridimensional networks could affect hydration and bioadhesion properties, morphology was assessed.

Figure 4 reports SEM images of transversal sections of CH 1, CH 1- HA and CH 1 – CS unloaded dressings and TA loaded dressings without lyoprotectans, and CH 1, CH 1- HA and CH 1 – CS dressings with glycerol and with mannitol.

CH 1 dressing showed a beehive structure with polyhedric cavities interconnected by pores having oval or round shapes. The cavities had dimensions of about 500  $\mu\text{m}$  while the pores ranged from 50 to 200  $\mu\text{m}$ . The presence of GAG did not change the system morphology while it markedly decreased the cavity dimensions that were around 200-300  $\mu\text{m}$  and furthermore the pore diameters that were of about 50  $\mu\text{m}$ . This difference in system porosity conceivably contributed to their hydration behavior. The TA loading did not modify the structure of the dressings.

The presence of glycerol as lyoprotectant did not substantially change dressing structure while the presence of mannitol caused a partially loss of polyhedric cavities and the structure resembled much more randomly organized sheets without marked modifications of the porosity. This modification could be responsible to the system behavior upon hydration and bioadhesion.

Since lyoprotectans did not markedly improve the technological properties of the dressings and considering mechanical, hydration and bioadhesive properties, lyoprotectant free systems prepared using chitosan at 1% w/w were considered for the further characterizations."

- 2) Bioadhesive properties paragraph was improved adding comments as follows:

"Figure 3 reports maximum force of bioadhesion (mN) all the dressings prepared: a) without lyoprotectant, b) with glycerol and c) with mannitol as lyoprotectans.

As for dressings without lyoprotectants (Fig. 3 a), chitosan concentration influenced bioadhesive behavior: CH 2 sponge-like dressing (containing higher chitosan amount) did not show bioadhesive propensity ( $F_{\text{max}}$  measured without biological substrate was not significantly different with respect to the value in presence of biological substrate – egg shell membrane) while CH 1 dressing (containing chitosan at lower amount) was characterized by good bioadhesive properties. Such a behavior is probably due to a different degree of entanglement between chitosan polymeric chains. In particular, the lowest chitosan concentration the lowest the entanglement and the highest the capability to form a bioadhesive joint with the biological substrate (Rossi, Ferrari, Bonferoni, Caramella, 2001).

Since zeta potential analysis confirmed that there was not a complete neutralization of CH with GAGs and both CH-HA and CH-CS had positive zeta potentials, the presence of GAG in dressings significantly enhanced the bioadhesive properties. The interaction between chitosan and GAG probably assisted bioadhesive joint consolidation, considering a higher concentration of carboxylic and OH residues in these systems with respect to that of CH 1. The highest presence of these groups able to form hydrogen bonds could consolidate bioadhesive properties of chitosan, that are mainly due to its positive charge density. Chitosan and GAG physical mixtures (CH-HApm, and CH-CSpm) did not show bioadhesive properties: these are easily inferred by the negligible solubility properties of chitosan at pH 7.2 phosphate buffer (hydration medium chosen to mimic wound bed exudate). Moreover CS or HA, as powders, were also considered and they showed a lack of bioadhesion in those conditions: this was probably due to slower hydration of HA during the test with respect to the lyophilized dressings and to the poor bioadhesive strenght of CS mainly caused by its low molecular weight.

In presence of lyoprotectans, both mannitol and glycerol (Fig. 3 b and c, respectively), the bioadhesive properties were less pronounced and were significant only for HA and CS dressings with mannitol. The presence of lyoprotectans, especially of mannitol, that increased system stiffness and probably decreased polymer chain mobility, could impair polymer capability to interact with the biological substrate.

Also bioadhesion is a crucial characteristic that should favor an intimate and prolonged contact between wound dressings and lesion, favoring blood absorption and avoiding formulation detachment to increase the hemostatic potential."

Reviewer #3

- 1) SEM analysis have been performed  
The results were commented as follows: "To understand if the system tridimensional networks could affect hydration and bioadhesion properties, morphology was assessed.  
Figure 4 reports SEM images of transversal sections of CH 1, CH 1- HA and CH 1 – CS unloaded dressings and TA loaded dressings without lyoprotectans, and CH 1, CH 1- HA and CH 1 – CS dressings with glycerol and with mannitol.  
CH 1 dressing showed a beehive structure with polyhedric cavities interconnected by pores having oval or round shapes. The cavities had dimensions of about 500  $\mu\text{m}$  while the pores ranged from 50 to 200  $\mu\text{m}$ . The presence of GAG did not change the system morphology while it markedly decreased the cavity dimensions that were around 200-300  $\mu\text{m}$  and furthermore the pore diameters that were of about 50  $\mu\text{m}$ . This difference in system porosity conceivably contributed to their hydration behavior. The TA loading did not modify the structure of the dressings.  
The presence of glycerol as lyoprotectant did not substantially change dressing structure while the presence of mannitol caused a partially loss of polyhedric cavities and the structure resembled much more randomly organized sheets without marked modifications of the porosity. This modification could be responsible to the system behavior upon hydration and bioadhesion.  
Since lyoprotectans did not markedly improve the technological properties of the dressings and considering mechanical, hydration and bioadhesive properties, lyoprotectant free systems prepared using chitosan at 1% w/w were considered for the further characterizations."
- 2) The characteristics of GAG were added in the text as follows:  
Hyaluronic Acid (HA) low MW 212000 Da; maximum charge density: number of negatively charged functional groups per repeated unit: 0.5 (Bioiberica, Barenz, Italy);  
Chondroitin sodium sulfate bovine 100 EP (CS) low MW 14000 Da, mixture of A (chondroitin 4 sulfate) and C (chondroitin 6 sulfate); maximum charge density: number of negatively charged functional groups per repeated unit: 1 (Bioiberica, Barenz, Italy).
- 3) The rationale of the paper was better stated in the introduction evidencing the different approach employed in comparison to previously published paper:  
The polysaccharides based systems should be more biocompatible rather than protein ones. In particular Collagen, one of the major components of ECM seems the best candidate to obtain dressings/scaffolds for wound reparation but in literature it is reported as immunogenic material due to possible helical- recognition by antibodies, due to 3D intact triple helix conformation, peculiar aminoacid sequence able to start antibody recognition, presence of non-helical terminal regions (telopeptides) (Lynn, Yannas and Bonfield, 2004; Olsen, Yang, Bodo, Chang et al., 2003). Moreover it could have concerns of species-to-species transmissible diseases (xenozoonoses) (Cataldo, Ursini, Lilla and Angelini, 2008). .....  
Sponge-like dressings should have advantages in application with respect to powdery hemostatic agents, especially in the treatment of intra-abdominal solid organ bleedings or injuries: if hemostatic agents are based on granules (microparticles) can leave residue in the lumen of the vessel and may occlude distal arterial flow. Moreover intraluminal dissemination of the clot, resulting in distal thrombosis, may occur (Khoshmohabat, Paydar, Kazemi and Dalfardi, 2016).
- 4) List of abbreviation was added.

Reviewer # 4

- 1) According to the reviewer's comment, a discussion about interaction of CH with GAG was added as follows: "As reported in literature, structure and stability of PECs strongly depend on different parameters such as concentrations of each polyelectrolyte, charge molar ratio, charge density, molar masses and chain flexibility but depend also on extrinsic parameters as pH, ionic strength and/or temperature (Kabanov, 2005; Feng, Leduc, and Pelton, 2008; Le Cerf, D., Pepin, A. S., Niang, P.M., Cristea et al., 2014).  
According to all these parameters, mixing oppositely charged polyelectrolytes could give two types of PECs dependently of charge stoichiometry: soluble PECs, leading to stable and transparent solutions, and insoluble PECs, with or without precipitation. The soluble PECs are obtained with an excess of anionic or cationic charges (Feng, Leduc, and Pelton, 2008; Kabanov and Zezin, 1984; Schatz, Domard, Viton, Pichot, et al., 2004) and this was the case of CH-HA and CH-CS. In fact, charge density (positive) is 0.006 mole/g for chitosan, 0.0013 mole/g for HA (negative) and 0.002 mole/g for CS (negative) with a clear excess of positive charges, in both cases. The charge molar ratio of CH – HA was 4.6 while that of CH – CS was 3.  
Moreover Denunziere, Ferrier, and Domard (1996) reported interaction between CS and CH was independent of CS sulfate substitution on 4 or 6 carbons."

Acetic acid titration and zeta potential were also performed and the results commented as follows: This was confirmed by zeta potential evaluation. CH 1 had a positive zeta potential of  $53.2 \pm 1.9$  (mean value  $\pm$ sd;  $n=3$ ) while HA and CS as solutions showed negative zeta potentials of  $-27.9 \pm 0.9$  and  $-16.8 \pm 1.2$ , respectively (mean value  $\pm$ sd;  $n=3$ ). CH 1 – HA and CH 1 – CS were characterized by positive zeta potentials of  $39.3 \pm 0.3$  and  $25.3 \pm 0.8$ , respectively (mean value  $\pm$ sd;  $n=3$ ). These results supported that the interaction between CH and GAGs did not cause a neutralization of the two polyelectrolytes mixed (CH and HA or CS) and an excess of positive charges was present. Moreover lyophilization caused acetic acid evaporation. In particular, acetic acid was added, to form chitosan acetate, in excess: 350  $\mu$ mol of acetic acid were added to 110  $\mu$ mol of chitosan per each dressing prepared, starting from chitosan at 1% w/w. The titration of acetic acid residues after lyophilization revealed that there was a residues of  $5 \pm 1$   $\mu$ mol per each systems independently of the addition of HA or CS. This is conceivably due to the almost total removal of acetic acid in excess (not involved in chitosan salification).

Moreover FT-IR analysis was performed and the results were commented as follows: Figure 5 reports the FT-IR spectra of CH 1, CH 1 – HA and CH 1 – CS HA and CH+CS dressings and of CH powder (in the inset) as comparison.




Figure 5: FT-IR spectra of CH 1, CH 1 – HA and CH 1 – CS HA and CH+CS dressings. In the inset the FTIR spectrum of CH powder (free CH) is reported as comparison.

The three spectra shared many common features both in the number and position of the peaks and seemed to be dominated by the FT-IR pattern of CH (free CH as powder), where the region around 1630 and 1540  $\text{cm}^{-1}$  is typical of the amide I and amide II stretching and bending modes (Radhakumary, Antony, Sreenivasan, 2011; Jayakumar, Prabhakaran, Nair, Tamura, 2010). Interestingly, the position of these peaks shifted to lower frequency with respect to free CH (i.e. not interacting with acetate ions) shown Figure 1 inset. In particular, the  $\text{-C=O}$  stretching of the amide I in free CH moved from 1652 to 1634  $\text{cm}^{-1}$  when it interacted with acetate ions and it remained in the same position even in the CH 1 - HA and CH 1 - CS systems. Moreover, a new peak around 1404  $\text{cm}^{-1}$  (correlated to the  $\text{-C-H-}$  bending) appeared in the spectra of CH 1 dressing with respect to free CH and was found also in the spectra of CH 1 - HA and CH 1 - CS. The two mentioned spectral features have been correlated to charge-charge neutralization (salification) which most probably occurred between CH and acetate ions and dominated the spectra of all the three systems shown in Figure 1 (Shanti Krishna, Radhakumary, Sreenivasan, 2015).

This suggests that, in presence of acetate ions, the charge-charge interaction, involving chitosan amino groups, was preferentially between CH and acetate and therefore the further addition of HA


and CS mostly interact with chitosan through less strong bonding such as polar interactions. Such results are in agreement with zeta potential values determined.

- 2) In the experimental part the hydration measurement procedure was described better to clarify the contact between the liquid and the sample:

“Dressings were placed on a 0.45  $\mu\text{m}$  membrane (HA, Millipore, I) that covered a container filled with pH 7.2 phosphate buffer (USP), simulating wound exudate. The liquid could freely cross the membrane dependently of the capability of each system to absorb liquid. At dry state (before the beginning of the hydration test) and at prefixed times during hydration (after the contact between each dressing and the membrane), the dressings were weighted and the amount of liquid absorbed was normalized by the weight of the dried dressing.”

- 3) It was not possible to include the picture of the instrument in the text because the restricted number of figured permitted (8 including also tables).

Hereafter you can find the picture of the instrument and the measuring systems. This was published in a review of ours “Sandri, G., Rossi, S., Bonferoni, M. C., Ferrari, F., Mori, M., Caramella, C. (2012) The role of chitosan as a mucoadhesive agent in mucosal drug delivery. *Journal of Drug Delivery Science and Technology*, 21, 275-284” and this was cited in the text.



Picture of texture analyzer apparatus (a), consisting of probe (b) and measuring system A/MUC (c) (Sandri, Rossi, Bonferoni, Ferrari et al., 2012, with permission)

- 4) Figure 3 blank meaning was inserted in the experimental part as follows: Blank measurements were performed by using a filter paper disc wetted with 100  $\mu\text{l}$  of isotonic saline solution (NaCl 0.9% w/v) instead of biological substrate: this allowed to evaluate cohesive properties of the sample.
- 5) The name of the samples was checked and rendered consistent in all the figures.
- 6) The in vitro “In vitro dynamic whole-blood clotting” paragraph was partially rewritten to better explain the results obtained.

“Figure 7 shows % hemoglobin absorbance profiles as function of time evaluated for a) unloaded dressings and b) TA loaded formulations.

A higher degree of hemoglobin absorbance indicates a slower clot formation rate.

Whole blood clotting formation was relatively slow and the hemoglobin absorbance reached the minimum level after about 420 s. A faster clot formation occurred in presence of all the dressings and

30 s immediately after the contact between blood and formulations the % of free hemoglobin was around 20-50%. The minimum level of hemoglobin absorbance was reached after about 300 s. Chitosan capability to bind and aggregate platelets causing agglutination of erythrocytes and activation of hemostasis was predominant in all the formulation considered also in presence of GAG. TA is a synthetic analogue of lysine and its antifibrinolytic activity is related to reversible bindings with four to five lysine receptor sites on plasminogen or plasmin: this prevents plasmin from binding to and degrading fibrin and preserves clot structure. TA showed a synergic activity with chitosan in enhancing clot formation: all the formulations reached the minimum in hemoglobin absorbance in about 180 s, presenting a better clotting performance with respect to unloaded dressings. TA CH 1 dressing allowed to maintain a % of hemoglobin at 420 s not significantly different from initial value, while CH 1 dressing determined a significant increase in % of hemoglobin comparing the initial value with respect to the final one (at 420 s). TA CH1 –HA and TA CH1- CS dressings proved to maintain clot integrity stable from the beginning up to 420 s, while the same compositions unloaded showed a partial clot modification at 90 s with a sharp increase in % of hemoglobin.

The presence of GAG slightly decreased the procoagulant activity of the dressings. In fact, HA and CS are reported in literature as anticoagulant materials. Fragments of HA having a molecular weight lower than 500 kDa, as it is the case, cause clot structure susceptible to mechanical deformations and softening (Komorowicz, Balazs, Varga, Szabo, et al., 2016). CS is a sulfated glycosaminoglycan with heparin-like activity (Pandolfi, M., Hedner, U., 1984). On this basis, the procoagulant activity of the systems seems exclusively due to chitosan and its synergic effect with TA.”

7) Figure 7 was deleted.

1 Freeze dried chitosan acetate dressings with glycosaminoglycans and traxenamic acid

2

3 Francesca Saporito<sup>1</sup>, Giuseppina Sandri<sup>1\*</sup>, Silvia Rossi<sup>1</sup>, Maria Cristina Bonferoni<sup>1</sup>, Federica Riva<sup>2</sup>, Lorenzo  
4 Malavasi<sup>3</sup>, Carla Caramella<sup>1</sup>, Franca Ferrari<sup>1</sup>

5

6 <sup>1</sup>Department of Drug Sciences, University of Pavia, Viale Taramelli 12, 27100 Pavia, Italy

7 <sup>2</sup>Department of Public Health, Experimental and Forensic Medicine, University of Pavia, via Forlanini 2,  
8 27100 Pavia, Italy

9 <sup>3</sup>Department of Chemistry, Physical Chemistry Section, University of Pavia, Viale Taramelli 12, 27100 Pavia,  
10 Italy

11

12

13

14

15

16

17 \*Corresponding author:

18 Prof. Giuseppina Sandri,

19 Department of Drug Sciences,

20 University of Pavia,

21 Viale Taramelli 12, 27100 Pavia, Italy

22 Tel: 0039 0382 987728

23 Fax: 0039 0382 422975

24 E-mail address: giuseppina.sandri@unipv.it

25



26 Abstract

27 Bleeding control plays an important role to increase survival in the early phase after a traumatic event.

28 The aim of the present work was the development of hemostatic sponge-like dressings based on chitosan, in  
29 association with glycosaminoglycans (GAG as chondroitin sulfate or hyaluronic acid) and the improvement of  
30 their hemostatic performance by loading tranexamic acid (TA). The dressings were prepared by  
31 lyophilization and were characterized for mechanical, hydration, bioadhesion properties and morphology.  
32 Moreover FTIR analysis was performed to understand the interactions between the different polyelectrolytes  
33 present in the dressing. Clotting was investigated in vitro by using rat whole blood. Moreover in vitro  
34 biocompatibility and proliferation were evaluated towards fibroblasts. Ex vivo proliferation properties were  
35 assessed by using human skin.

36 All the dressings were characterised by mechanical, hydration and bioadhesion properties suitable to be  
37 applied on bleeding wounds and to absorb bleeding or wound exudate, avoiding tissue dehydration. TA  
38 release was fast and TA and chitosan showed a synergic effect to speed up clotting. The dressings were  
39 biocompatible and able to sustain cell proliferation in vitro and ex vivo in human epidermis. In conclusion,  
40 sponge-like dressings based on chitosan and GAG and loaded with TA are an effective tool to enhance  
41 hemostasis and healing in bleeding wounds.

42

43 Highlights

44 Chitosan and glycosaminoglycan dressings are characterized by mechanical, hydration and bioadhesive  
45 properties suitable to be applied on bleeding wounds.

46 Chitosan and glycosaminoglycan interaction was studied by FTIR and dressing morphology was  
47 characterized by SEM.

48 Chitosan and tranexamic acid have a synergic effect in clot formation.

49

50 Keywords: chitosan, glycosaminoglycans, tranexamic acid, hemostasis, wound healing

51

52

53

54

55

56

57

58

59

60

- 61 Abbreviations
- 62 CH: chitosan
- 63 GAGs: glycosaminoglycans
- 64 ECM: extracellular matrix
- 65 HA: hyaluronic acid
- 66 CVS: chondroitin sulfate
- 67 TA: tranexamic acid
- 68 GM: growth medium
- 69 g: glycerol
- 70 m: mannitol
- 71  $I_s$ : absorbance of sample
- 72  $I_r$ : absorbance of reference value
- 73 NHDFs: normal human dermal fibroblasts from juvenile foreskin
- 74 FCS: foetal calf serum
- 75 MTT: (3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium Bromide)
- 76 PEC: polyelectrolyte complex

77 1. Introduction

78 Since 2001 (at the beginning of Afghanistan and Iraq military conflicts), many medical advances in military  
79 trauma care have been made to decrease morbidity and mortality and in particular, efforts have been made  
80 to control internal and external hemorrhage. However massive bleeding remains the leading cause of  
81 combat death and the second leading cause of death after traumatic brain injury in the civilian sector  
82 (Bennet, 2017; Champion, Bellamy, Roberts and Leppaniemi, 2003). Moreover in surgery, the reduction of  
83 bleeding can positively influence patient's prognosis (Li et al., 2016). Thus, bleeding control plays an  
84 important role not only to increase survival but also to prevent the development of multiple organ failure in  
85 the early phase after a traumatic event (Shields and Crowley, 2014).

86 Advanced topical hemostatic devices (including bandages, fibrin glue, liquids, powders, gels, and scaffolds –  
87 generally referred to as dressings) have been developed to control hemorrhages, to reduce mortality and  
88 prevent further complications (Seon, Lee, Kwon, Kim, et al., 2017). These dressings can be grouped into  
89 three classes by mechanism of action: including blood factor concentrators, which concentrate blood cellular  
90 and protein components to promote clot formation, bioadhesive agents having strong adherence to tissues  
91 and, procoagulant supplementary, which provide local concentration of procoagulat blood factors (Granville-  
92 Chapman, Jacobs, and Midwinter, 2011). Furthermore, dressings cover wounds preventing risk of infections  
93 (Seon et al., 2017).

94 Many types of natural polysaccharides have proposed as dressing biomaterials. In particular, chitosan (CH),  
95 a linear cationic polysaccharide based on glucosamine and N-acetyl glucosamine, obtained by partial chitin  
96 deacetylation, is well known as hemostatic agent. CH is able to enhance coagulation, by both  
97 hemagglutination and promoting platelet activation. In presence of blood, CH forms a solid clot due to  
98 thrombin and platelet activation, fibrin polymerization and fibrin fibers cross linking by FXIIIa (Marchand,  
99 Rivard, Sun, and Hoemann; 2009; Iliescu, Hoemann, Shive, Chenite et al., 2008) and CH is able to stabilize  
100 clot structure preventing its lysis (Hoemann et al., 2007). Moreover, it possess other crucial properties  
101 fundamental in wound healing: it is biodegradable and characterized by antimicrobial properties.  
102 Furthermore, CH supports extracellular matrix regeneration stimulating granulation tissue formation,  
103 activating fibroblasts (Francesko and Tzanov, 2011) and enhancing their proliferation and migration (Sandri  
104 et al., 2011) in the early phases of healing. Moreover, it is able to enhance remodeling process increasing  
105 also angiogenesis.

106 Glycosaminoglycans (GAGs) play a crucial role in different stages of skin tissue regeneration and  
107 maturation, being important components of its extracellular matrix (ECM). Moreover, GAGs are able to bind  
108 proteins including several chemokines and growth factors. The polysaccharidic structure of  
109 glycosaminoglycans as well as the presence, position and number of sulfate groups within the polymer chain  
110 plays an important role on these GAG-protein interactions. Among glycosaminoglycans, chondroitin sulfate  
111 (CS) and hyaluronic acid (HA), are naturally present in mammals and have an important role in the healing  
112 process.

113 CS is a sulfated polysaccharide based on N-acetylgalactosamine-glucuronic acid disaccharide units. It is  
114 able to interact with different important positively charged biological molecules, such as growth factors,  
115 chemokines, cytokines and adhesion molecules, involved in tissue healing and it prolongs their activities by  
116 charge-charge interactions, avoiding their enzymatic degradation (Silbert and Sugumaran, 2002; Yamada  
117 and Sugahara, 2008). HA is a linear polysaccharide composed of a dimeric repeating unit of D-glucuronic

118 acid and N-acetyl-D-glucosamine and, during the tissue injuries, it takes part to the wound healing and  
119 coagulation process forming, together with fibrin, a matrix support for fibroblast migration and proliferation  
120 (Chen and Abatangelo, 1999; Jiang, Liang and Noble, 2007).

121 **The polysaccharides based systems should be more biocompatible rather than protein ones. In particular**  
122 **Collagen, one of the major components of ECM seems the best candidate to obtain dressings/scaffolds for**  
123 **wound reparation but in literature it is reported as immunogenic material due to possible helical- recognition**  
124 **by antibodies, due to 3D intact triple helix conformation, peculiar aminoacid sequence able to start antibody**  
125 **recognition, presence of non-helical terminal regions (telopeptides) (Lynn, Yannas and Bonfield, 2004;**  
126 **Olsen, Yang, Bodo, Chang et al., 2003). Moreover it could have concerns of species-to-species**  
127 **transmissible diseases (xenozoonoses) (Cataldo, Ursini, Lilla and Angelini, 2008).**

128 Given this premises, the aim of the present work was the development of hemostatic sponge-like dressings  
129 based on chitosan (CH), in association with chondroitin sulfate (CS) and hyaluronic acid (HA) and loaded  
130 with tranexamic acid (TA), to be used in case of massive bleeding.

131 Tranexamic acid (TA) is a synthetic derivative of the aminoacid lysine and acts as antifibrinolytic agent by  
132 reversibly blocking lysine sites on plasminogen molecules (Dunn and Goa, 1999). In particular, TA is able to  
133 inhibit fibrinolysis by displacing plasminogen from fibrin and by avoiding its degradation (Ker, Edwards,  
134 Rerei, Shakur and Roberts, 2012).

135 **Sponge-like dressings should have advantages in application with respect to powdery hemostatic agents,**  
136 **especially in the treatment of intra-abdominal solid organ bleedings or injuries: if hemostatic agents are**  
137 **based on granules (microparticles) can leave residue in the lumen of the vessel and may occlude distal**  
138 **arterial flow. Moreover intraluminal dissemination of the clot, resulting in distal thrombosis, may occur**  
139 **(Khoshmohabat, Paydar, Kazemi and Dalfardi, 2016).**

140 TA loaded sponge-like dressings were prepared by freeze-drying and were characterized by hydration,  
141 mechanical, bioadhesion properties and morphology. **Moreover, FTIR analysis was performed to understand**  
142 **the interactions bet ween the different polyelectrolytes present in the dressing.** The release profile of TA was  
143 evaluated in isotonic solution (NaCl 0.9%) by using Franz diffusion cells. The hemostatic performance of the  
144 systems was evaluated by means of a dynamic whole-blood clotting test. Furthermore, in vitro  
145 cytocompatibility and proliferation tests were assessed by using NHDFs (normal human dermal fibroblasts  
146 from juvenile foreskin). Finally, proliferation properties of TA loaded sponge-like dressings were evaluated by  
147 means of an ex-vivo test on human skin.

148

## 149 2. Experimental part

### 150 2.1. Materials

151 The following materials were used: Chitosan (CH) low MW 251000 Da, deacetylation degree 98%, **maximum**  
152 **charge density: number of positively charged functional groups per repeated unit: 0.98** (ChitoClear,  
153 Siiiglufjordur-Iceland); Hyaluronic Acid (HA) low MW 212000 Da; **maximum charge density: number of**  
154 **negatively charged functional groups per repeated unit: 0.5** (Bioiberica, Barenz, Italy); **Chondroitin sodium**  
155 **sulfate bovine 100 EP (CS) low MW 14000 Da, mixture of A (chondroitin 4 sulfate) and C (chondroitin 6**  
156 **sulfate); maximum charge density: number of negatively charged functional groups per repeated unit: 1**  
157 (Bioiberica, Barenz, Italy); Trans-4 (amino-methyl) cyclohexanecarboxylic acid (Sigma Aldrich, Milan-Italy);  
158 Glycerol (g) 30° Be (Carlo Erba, Italy); D-Mannitol (Fluka, France).

159

## 160 2.2. Methods

### 161 2.2.1. Sponge-like dressing preparation

162 CH was hydrated in acetic acid 1% w/w (glacial acetic acid, Sigma Aldrich, Italy) under gentle stirring at  
163 room temperature. Acetate was used as counterion to obtain chitosan salification in mild pH conditions and it  
164 was preferred to hydrochloric acid because chitosan fragmentation could occur in HCl environment also at  
165 low molarity (Sabnis, Block, 2000).

166 HA and CS were hydrated in distilled water under gentle stirring at room temperature. The two polymeric  
167 solutions were mixed 1:1 weight ratio to obtain polymeric mixtures. Systems containing CH alone were mixed  
168 1:1 weight ratio with bidistilled water. Final acetic acid concentration in the polymeric systems was 0.5% w/w.  
169 CH 1 - HA and CH 1 - CS mixtures and CH 1, were subjected to zeta potential evaluation. Measurements  
170 were carried out at 25°C by means of a Malvern Zetasizer Nano ZS90 (Malvern Ltd., UK). HA and CS  
171 solutions, prepared in the same concentrations used for CH 1 - HA and CH 1 - CS mixtures but without CH  
172 were also tested.

173 In two series of preparations of CH 1 - HA and CH 1 - CS mixtures and CH 1, glycerol or mannitol were  
174 added as lyoprotectants. Polymeric solutions appeared transparent without visible precipitate. As for TA  
175 loaded systems drug was added to the polymeric mixture at 0.75% w/w. Two ml of each mixture were poured  
176 into each well of 12-well plate (well area 3.8 cm<sup>2</sup>). In the TA loaded systems the drug was 4 mg/cm<sup>2</sup>. All the  
177 polymeric solutions were frozen at -40°C overnight and freeze-dried (Heto 15, Analitica De Mori, I) for 24 h.  
178 All the dressings prepared were 5 mm thick (sd ± 0.52).

179 CH, HA and CS were at 5 mg/cm<sup>2</sup> concentration in CH 1 dressings; CH was at 10 mg/cm<sup>2</sup> concentration in  
180 CH 2 dressings, glycerol was at 1.3 mg/cm<sup>2</sup> while mannitol was at 10.5 mg/cm<sup>2</sup>.

181 Dressings were re-solubilized in distilled water to check the eventual residues of acetic acid (2 g of distilled  
182 water per each dressing). pH of each sample was measured by means of a pHmeter (pH 210  
183 Microprocessor, Hanna Instruments, Italy) and the acetic acid excess was titrated by means of acid-base  
184 titration by using phenolphthalein as indicator and NaOH 0.1 M (Carlo Erba, Italy).

185

### 186 2.2.2. Sponge-like dressing characterization

#### 187 2.2.2.1. Penetrometry measurements

188 Sponge-like dressings were subjected to penetrometry measurements by means of a texture analyzer  
189 (TA.XT plus, Stable Microsystems, ENCO, Spinea, I), equipped with a cylinder probe (10 mm, P10), to  
190 evaluate the resistance to compression. Each dressing was placed onto the apparatus base and the probe  
191 was lowered at 1 mm/s speed. Maximum force of resistance to compression (F<sub>max</sub>) was determined as the  
192 maximum force required to penetrate into the sponge up to 2.5 mm.

193

#### 194 2.2.2.2. Hydration measurements

195 Dressings were placed on a 0.45 µm membrane (HA, Millipore, I) that covered a container filled with pH 7.2  
196 phosphate buffer (USP), simulating wound exudate. The liquid could freely cross the membrane dependently  
197 of the capability of each system to absorb liquid. At dry state (before the beginning of the hydration test) and  
198 at prefixed times during hydration (after the contact between each dressing and the membrane), the

199 dressings were weighted and the amount of liquid absorbed was normalized by the weight of the dried  
200 dressing.

201

#### 202 2.2.2.4. Bioadhesion measurements

203 Bioadhesion measurements were performed using texture analyzer (TA.XT plus, Stable Microsystems,  
204 ENCO, Spinea, I) equipped with a 1 kg load cell, a cylinder probe having a diameter of 10 mm (P10) and the  
205 measuring system A/MUC (adhesion test system) (Sandri, Bonferoni, D'Autilia, Rossi et al., 2013; Szucs,  
206 Sandri, Bonferoni, Caramella et al., 2008). The measuring system A/MUC consists of a support in which a  
207 biological substrate can be fixed. In this case, the biological substrate was egg shell membrane (Tao, Lu,  
208 Sun, Gu et al., 2009), chosen to mimic damaged skin, wetted with 100  $\mu$ l of isotonic saline solution (NaCl  
209 0.9% w/v). To obtain the membrane, the egg shell was placed in a 0.5 M HCl solution for 1 h. Sponge like  
210 dressings, having diameter of 10 mm, were stuck with cyanoacrylate glue to the cylinder probe and hydrated  
211 with 100  $\mu$ l of pH 7.2 phosphate buffer (USP). The sample and the biological substrate were put in contact  
212 under a preload of 0.02 N for 3 min. The cylinder probe was then moved upward at a prefixed speed of 2.5  
213 mm/s up to the complete separation of the bioadhesive interface (egg shell membrane-sample). The  
214 maximum force of detachment ( $F_{max}$ ) was recorded as a function of displacement.

215 Blank measurements were performed by using a filter paper disc wetted with 100  $\mu$ l of isotonic saline  
216 solution (NaCl 0.9% w/v) instead of biological substrate: this allowed to evaluate cohesive properties of the  
217 sample. As comparison, two physical mixtures (CH-HAp<sub>m</sub> and CH-CS<sub>pm</sub>) having the same polymer  
218 composition than sponge-like dressings were evaluate. Moreover the bioadhesion of CS and HA as powders  
219 (CS<sub>p</sub> and HAp) were compared to understand the contribution of GAG to bioadhesion. In these latter cases,  
220 the same experimental conditions (hydration and sample weight) were used.

221

#### 222 2.2.2.5. Morphology

223 Dressing morphology was analyzed by means of scanning electron microscopy (SEM, Tescan, Mira3XMU,  
224 ARVEDI Center, University of Pavia). Samples were sputtered by means of graphite deposition under  
225 vacuum.

226

#### 227 2.2.2.6. FT-IR measurements

228 FT-IR spectra were obtained using a Nicolet FT-IR iS10 Spectrometer (Nicolet, Madison, WI, USA) equipped  
229 with ATR (Attenuated Total Reflectance) sampling accessory (Smart iTR with ZnSe plate) by co-adding 256  
230 scans in the 4000–650  $\text{cm}^{-1}$  range at 4  $\text{cm}^{-1}$  resolution.

231

#### 232 2.2.2.7. TA release measurements

233 TA release measurements were performed in vitro by using Franz cells (vertical glass diffusion cell, orifice  
234 diameter 20 mm, PermeGear Inc., USA). A cellulose acetate membrane (pore size 0.45  $\mu$ m, diameter 25  
235 mm) was placed between the donor and the receptor chambers. The cells were thermoset at 32°C by means  
236 of a water jack. Isotonic solution (NaCl 0.9% w/v) was used as receiving phase. Each dressing was placed in  
237 the donor chamber and wetted with 100  $\mu$ l of isotonic solution. At prefixed times, 500  $\mu$ l of receiving phase  
238 were collected and the amount of drug released was assayed by means of a spectrophotometric method  
239 (Ansari, Raza, and Rehman, 2005). This method is based on the colorimetric detection of the Ruhemann's

240 purple resulting from ninhydrin and TA reaction via oxidation deamination of TA primary amino group,  
241 followed by the condensation of the reduced ninhydrin in the basic medium at pH 8.0. TA stock solution was  
242 prepared in NaCl 0.9 % w/v at 1 mg/ml concentration and a calibration curve was prepared with TA  
243 concentrations ranging from 1 mg/ml to 0.1 mg/ml. 1 ml of ninhydrin reagent (0.2 % w/w ninhydrin (Carlo  
244 Erba, Milan, I) in methanol ) and 0.5 ml of 20 mM phosphate buffer at pH 8.0 were added to 200 µl of each  
245 sample. Each sample was heated at 90 °C for 20 min in a shaking bath, subsequently they were cooled at  
246 room temperature and their absorbance was read at 565 nm wavelength (Lamba 25, Perkin Elmer, I). The  
247 method was linear in the concentration range from 1 mg/ml to 0.1 mg/ml with R<sup>2</sup> higher than 0.995.

248

#### 249 2.2.2.8. In vitro dynamic whole-blood clotting

250 The hemostatic activity of sponge-like dressings was evaluated using rat whole blood pooled from 6 male  
251 rats (Wistar 200–250 g). All animal experiments were carried out in full compliance with the standard  
252 international ethical guidelines (European Communities Council Directive 86/609/EEC) and approved by  
253 Italian Health Ministry (D.L. 116/92). The study protocol was approved by the Local Institutional Ethics  
254 Committee of the University of Pavia for the use of animals. The whole blood was supplemented with 10%  
255 v/v of acid-citrate-dextrose (ACDC, 38 mM citric acid/ 75 mM trisodium citrate /100 mM dextrose) to avoid the  
256 coagulation during the storage at 4°C (Quan, Lia, Luana, Yuana, et al., 2015; Ong, Wu, Moochhala, Tan, et  
257 al., 2008; Sudheesh Kumar, Lakshmanan, Anilkumar, Ramya, et al., 2012). Just before experiments, the  
258 anticoagulant activity of ACDC was inhibited by adding 100 µl of saturated CaCl<sub>2</sub> solution to 50 µl of blood.

259 50 µl volume of fresh blood was dropped onto unloaded and TA loaded sponge dressings (5 mm in  
260 diameter) placed in 50 ml glass beaker. After prefixed contact times, 10 ml distilled water was slowly poured  
261 in beaker without disturbing the clotted blood. The beaker was gently shaken for 2 minutes to suspend free  
262 red blood cells, not entrapped in the clot. The absorbance of each resulting sample, was assayed by means  
263 of spectrophotometric detection at 542 nm wavelength (Lamba 25, Perkin Elmer, I). As reference, fresh  
264 blood was considered.

265 The content of hemoglobin was quantified by the following equation:

$$266 \text{ Hemoglobin absorbance \%} = I_s/I_r \times 100$$

267 where I<sub>s</sub> is the absorbance of the resulting sample, and I<sub>r</sub> is the absorbance of the reference value (blood or  
268 blood/TA (Ong, Wu, Moochhala, Tan, et al., 2008; Sudheesh Kumar, Lakshmanan, Anilkumar, Ramya, et al.,  
269 2012).

270

#### 271 2.2.2.9. In vitro biocompatibility and proliferation

272 NHDFs (normal human dermal fibroblasts from juvenile foreskin, Promocell GmbH, Heidelberg, G) were  
273 used between the 2<sup>nd</sup> and 5<sup>th</sup> passage, for all the experiments.

274 Fibroblasts were grown in presence of Dulbecco's modified Eagle medium (Sigma, I) and supplemented with  
275 10% fetal calf serum (FCS, Euroclone, I) with 200 IU/ml penicillin, and with 0.2 mg/ml streptomycin (Sigma, I)  
276 and kept at 37° C in a 5% CO<sub>2</sub> atmosphere with 95% relative humidity (RH).

277 Fibroblasts were seeded in each well of 96-well plates (area 0.34 cm<sup>2</sup>) at a seeding density of 10<sup>5</sup> cells/cm<sup>2</sup>.  
278 Cells were grown 24 h to obtain sub-confluence.

279 3.5 x 10<sup>4</sup> cells/well (area 0.34 cm<sup>2</sup>) were seeded in a 96-well plate and grown to confluence for 24 h.

280 After 24 h cells were washed with saline solution and placed in contact with 200  $\mu$ l of CH, CH-CS and CH-  
281 HA polymeric mixtures (prepared as reported in the section 2.2.1.) at 1:20 (CH, CS or HA at 500  $\mu$ g/ml,  
282 solubilized in cell growth medium) and 1:50 dilution with growth medium (GM) (CH, CS or HA at 200  $\mu$ g/ml).  
283 After dilution, all the samples were transparent without visible precipitate. TA having the same concentration  
284 as in the loaded polymeric mixtures and GM were used as control. Cell substrates were incubated for 3 h  
285 (biocompatibility test) and for 24 h (proliferation test) with the samples, then the medium was removed and  
286 the MTT test was performed. Briefly, MTT test is based on the activity of mitochondrial dehydrogenases of  
287 vital cells that convert MTT in formazan (Sandri, Aguzzi, Rossi, Bonferoni et al., 2017). At this purpose, 50  $\mu$ l  
288 of MTT solution (Sigma Aldrich, I) at 2.5 mg/ml concentration in HBSS (Hank's Buffered Salt Solution) pH 7.4  
289 was put in contact with each cell substrate for 3 h. The reagent was removed from each well, and the  
290 substrates were washed with 200  $\mu$ l of PBS. After the removal of PBS, 100  $\mu$ l of DMSO was put in each well,  
291 and the absorbance was assayed at 570 nm by means of an ELISA plate reader (Imark Absorbance Reader,  
292 Biorad, I), with a reference wavelength of 690 nm. Cell viability was calculated as % ratio between the  
293 absorbance of each sample and the absorbance of cell substrate maintained in contact with growth medium.  
294

#### 295 2.2.2.10. Ex vivo proliferation on human skin biopsy

296 To analyze the effects of dressings on wound healing, an ex vivo human skin model was used to reproduce  
297 in vivo physiological conditions (Mori, Rossi, Ferrari, Bonferoni et al., 2016). Adult healthy human skin  
298 biopsies were clinically obtained from surgery for breast reduction of different age donors (range 35-60 years  
299 old), after obtaining informed consent. Surgical biopsy (about 4x8 cm) was cut into smaller fragments (about  
300 0.6x0.6 cm) and a skin circular portion (including epidermis and dermis) was centrally removed with aseptic  
301 circular punch (diameter: 3 mm). Each fragment was placed into Transwell<sup>®</sup> inserts (growing area: 0.33 cm<sup>2</sup>,  
302 Corning<sup>®</sup> Costar<sup>®</sup>, Sigma, I) in 24-well-plate (membrane pore size: 0.4  $\mu$ m) and circular portions of each  
303 dressing, having the same diameter of punch, were applied in correspondence of skin lesion.

304 The samples were maintained in culture in presence of Dulbecco's modified Eagle medium (Sigma, I) and  
305 supplemented with 10% fetal calf serum (FCS, Euroclone, I) with 200 IU/ml penicillin, and with 0.2 mg/ml  
306 streptomycin (Sigma, I) and kept at 37° C in a 5% CO<sub>2</sub> atmosphere with 95% relative humidity (RH).

307 The medium (900  $\mu$ l/each well) was added into well basal compartment to maintain skin viability, avoiding  
308 skin dehydration and ensuring an adequate supply of nutrients through hypodermis. After different times (24  
309 and 72 h and 7 days) of culture, the biopsies were fixed with 4% paraformaldehyde in 0.1 M phosphate  
310 buffer, pH 7.4, for 24 h, and processed for histological analysis (Riva, Casasco, Nespoli, Icaro Cornaglia, et  
311 al., 2007). Briefly, the fragments were dehydrated through graded concentrations of ethanol and embedded  
312 in paraffin. 8  $\mu$ m sections were obtained by means of a microtome (Leitz, G), rehydrated and processed for  
313 immunohistochemical reactions for bromodeoxyuridine (BrdU) incorporation. The sections were incubated  
314 with primary antibody anti-BrdU (Ge Healthcare, UK) overnight at appropriate dilution (1:100), the primary  
315 antibody anti-BrdU was reacted by using MACH 1 Universal HRP-Polymer Detection kit (Biocare Medical,  
316 USA). At this purpose the sections were reacted with MACH 1 Mouse probe for 15 min and subsequently  
317 with HRP-Polymer (horseradish peroxidase polymer) for 30 min and finally with Biocare's Betazoid DAB for 5  
318 min. Finally, the sections were dehydrated and mounted with DPX mounting medium (a mixture of distyrene,  
319 a plasticizer, dissolved in toluene-xylene, Sigma, I).



320 Skin sections obtained in the middle of the lesions were observed at the magnification of 20X under a light  
321 microscope Axiophot (Zeiss, G) equipped with a digital camera. Image J program was used to analyze  
322 images, counting cell nuclear positivity in a section area larger 2 mm at right and left side than the lesions.

323  
324  
325  
326

#### 327 2.2.2.11. Statistical analysis

328 Statistical differences were evaluated by means of a non-parametric test: Mann Whitney (Wilcoxon) W test,  
329 (Stat Graphics 5.0, Statistical Graphics Corporation, MD, USA). Differences were considered significant at  
330  $p < 0.05$ ; only significant differences are evidenced in the figures as asterisks.


331

### 332 3. Results and discussion

#### 333 3.1. Sponge-like dressing technological properties

##### 334 3.1.1 Mechanical properties

335 Figure 1 reports the results of mechanical resistance as maximum force of penetration of the dressings  
336 without lyoprotectant and with glycerol or mannitol as lyoprotectants.



337

338 Figure 1: mechanical resistance as maximum force of penetration ( $F_{max}$ , mN) of the dressings without  
339 lyoprotectant and with glycerol or mannitol as lyoprotectants (mean values  $\pm$ sd;  $n=6$ )

340



341 The increase of chitosan amounts in the dressings increased the mechanical resistance of the formulations:  
342 stiffness was significantly greater when lyoprotectants (glycerol or mannitol) were included in the  
343 formulations. The presence of HA in the dressings caused a significantly increase in the mechanical  
344 resistance and HA based formulation with mannitol, as lyoprotectant, was characterized by the higher  $F_{max}$   
345 value to indicate a more rigid structure. This behavior could probably due to the high molecular weight of HA,  
346 with respect to CS, that could dramatically strengthen the tridimensional network of the system. It is  
347 conceivable that HA interacted with chitosan during the preparation procedure, forming a polyelectrolyte

348 complex (PEC) between chitosan and hyaluronate. Since both CH and HA have similar molecular weight the  
349 interaction between the two polymers should be able to form a highly crosslinked structure.  
350 On the contrary, the presence of CS in the formulation did not significantly change the stiffness of the  
351 dressings. This is probably due to the resulting PEC formed by an interaction between CS and CH: CS is  
352 characterized by a molecular weight 18 folds lower than that of CH, moreover sulfate groups of CS (more  
353 acid with respect to carboxylic group) could cause a coiled structure less prone to polymer chain  
354 entanglements. This probably rendered the dressing structure less stiff.  
355 As reported in literature, structure and stability of PECs strongly depend on different parameters such as  
356 concentrations of each polyelectrolyte, charge molar ratio, charge density, molar masses and chain flexibility  
357 but depend also on extrinsic parameters as pH, ionic strength and/or temperature (Kabanov, 2005; Feng,  
358 Leduc, and Pelton, 2008; Le Cerf, D., Pepin, A. S., Niang, P.M., Cristea et al., 2014).  
359 According to all these parameters, mixing oppositely charged polyelectrolytes could give two types of PECs  
360 dependently of charge stoichiometry: soluble PECs, leading to stable and transparent solutions, and  
361 insoluble PECs, with or without precipitation. The soluble PECs are obtained with an excess of anionic or  
362 cationic charges (Feng, Leduc, and Pelton, 2008; Kabanov and Zezin, 1984; Schatz, Domard, Viton,  
363 Pichot, et al., 2004) and this was the case of CH-HA and CH-CS. In fact, charge density (positive) is 0.006  
364 mole/g for chitosan, 0.0013 mole/g for HA (negative) and 0.002 mole/g for CS (negative) with a clear excess  
365 of positive charges, in both cases. The charge molar ratio of CH – HA was 4.6 while that of CH – CS was 3.  
366 Moreover Denunziere, Ferrier, and Domard (1996) reported interaction between CS and CH was  
367 independent of CS sulfate substitution on 4 or 6 carbons.  
368 This was confirmed by zeta potential evaluation. CH 1 had a positive zeta potential of  $53.2 \pm 1.9$  (mean  
369 value  $\pm$ sd; n=3) while HA and CS as solutions showed negative zeta potentials of  $-27.9 \pm 0.9$  and  $-16.8 \pm 1.2$ ,  
370 respectively (mean value  $\pm$ sd; n=3). CH 1 – HA and CH 1 – CS were characterized by positive zeta potentials  
371 of  $39.3 \pm 0.3$  and  $25.3 \pm 0.8$ , respectively (mean value  $\pm$ sd; n=3). These results supported that the interaction  
372 between CH and GAGs did not cause a neutralization of the two polyelectrolytes mixed (CH and HA or CS)  
373 and an excess of positive charges was present.  
374 Moreover lyophilization caused acetic acid evaporation. In particular, acetic acid was added, to form chitosan  
375 acetate, in excess: 350  $\mu$ mol of acetic acid were added to 110  $\mu$ mol of chitosan per each dressing prepared,  
376 starting from chitosan at 1% w/w. The titration of acetic acid residues after lyophilization revealed that there  
377 was a residues of  $5 \pm 1$   $\mu$ mol per each systems independently of the addition of HA or CS. This is conceivably  
378 due to the almost total removal of acetic acid in excess (not involved in chitosan salification).


### 379 380 3.1.2. Hydration properties

381 Figure 2 reports buffer (pH 7.2 phosphate buffer, to mimic wound exudates) taken up a function of time for all  
382 the dressings prepared: a) without lyoprotectant, b) with glycerol and c) with mannitol as lyoprotectants.  
383 Considering all the compositions with and without lyoprotectants, chitosan based dressings were  
384 characterized by higher buffer taken up vs time profile with respect to those of chitosan and GAG systems;  
385 moreover chitosan dressings based on higher CH amounts, showed higher hydration profile even not  
386 significantly different from hydration capability of dressing based on lower CH amounts. Dressings based on  
387 chitosan and GAG were characterized by significantly lower hydration profiles, independently of both the  
388 presence and type of lyoprotectants. All the systems showed a high hydration capacity in the first hour: it is

389 conceivable that chitosan was likely to create a lower pH environment at the dressing/liquid interface and this  
390 caused a high liquid absorption probably due chitosan gelation. Subsequently, chitosan poor solubility at  
391 neutral pH (pKa 6.5) prevailed over its buffering properties and liquid absorption stopped. The presence of  
392 GAG further decreased system hydration probably due to the interpolymer interaction between chitosan and  
393 hyaluronic acid or chondroitin sulfate.



430  
431  
432  
433  
434  
435  
436  
437  
438  
439  
440  
441  
442  
443  
444  
445  
446  
447  
448  
449  
450  
451



452 Figure 2: liquid taken up (pH 7.2 phosphate buffer) as function of time for all the dressings prepared: a)  
453 without lyoprotectant, b) with mannitol and c) with glycerol as lyoprotectans (mean values±sd; n=6)

454 Glycerol did not markedly change the hydration properties of CH and CH in association with GAG. On the  
455 contrary, mannitol substantially decreased the hydration capacity of the systems: this could be related to stiff  
456 structure of the dressings, which could slow down and impair liquid penetration into the dressings.

457 Hydration behavior is a crucial point in dressings to ensure hemostasis, to absorb wound exudate and to  
458 avoid wound bed dehydration, enhancing granulation phase and healing.

459

### 460 3.1.3. Bioadhesion properties

461 Figure 3 reports maximum force of bioadhesion (mN) all the dressings prepared: a) without lyoprotectant, b)  
462 with glycerol and c) with mannitol as lyoprotectants.

463 As for dressings without lyoprotectants (Fig. 3 a), chitosan concentration influenced bioadhesive behavior:  
464 CH 2 sponge-like dressing (containing higher chitosan amount) did not show bioadhesive propensity (F<sub>max</sub>  
465 measured without biological substrate was not significantly different with respect to the value in presence of  
466 biological substrate – egg shell membrane) while CH 1 dressing (containing chitosan at lower amount) was  
467 characterized by good bioadhesive properties. Such a behavior is probably due to a different degree of  
468 entanglement between chitosan polymeric chains. In particular, the lowest chitosan concentration the lowest  
469 the entanglement and the highest the capability to form a bioadhesive joint with the biological substrate  
470 (Rossi, Ferrari, Bonferoni, Caramella, 2001).

471 Since zeta potential analysis confirmed that there was not a complete neutralization of CH with GAGs and  
472 both CH-HA and CH-CS had positive zeta potentials, the presence of GAG in dressings significantly  
473 enhanced the bioadhesive properties. The interaction between chitosan and GAG probably assisted  
474 bioadhesive joint consolidation, considering a higher concentration of carboxylic and OH residues in these  
475 systems with respect to that of CH 1. The highest presence of these groups able to form hydrogen bonds  
476 could consolidate bioadhesive properties of chitosan, that are mainly due to its positive charge density.  
477 Chitosan and GAG physical mixtures (CH-HA<sub>pm</sub>, and CH-CS<sub>pm</sub>) did not show bioadhesive properties: these  
478 are easily inferred by the negligible solubility properties of chitosan at pH 7.2 phosphate buffer (hydration  
479 medium chosen to mimic wound bed exudate). Moreover CS or HA, as powders, were also considered and  
480 they showed a lack of bioadhesion in those conditions: this was probably due to slower hydration of HA  
481 during the test with respect to the lyophilized dressings and to the poor bioadhesive strength of CS mainly  
482 caused by its low molecular weight.

483 In presence of lyoprotectants, both mannitol and glycerol (Fig. 3 b and c, respectively), the bioadhesive  
484 properties were less pronounced and were significant only for HA and CS dressings with mannitol. The  
485 presence of lyoprotectants, especially of mannitol, that increased system stiffness and probably decreased  
486 polymer chain mobility, could impair polymer capability to interact with the biological substrate.

487 Also bioadhesion is a crucial characteristic that should favor an intimate and prolonged contact between  
488 wound dressings and lesion, favoring blood absorption and avoiding formulation detachment to increase the  
489 hemostatic potential.

490



491

492


493

494

495  
496  
497  
498  
499  
500  
501  
502  
503  
504  
505  
506  
507  
508  
509  
510  
511  
512  
513  
514  
515  
516  
517  
518  
519  
520  
521  
522  
523  
524  
525  
526  
527  
528  
529



530  
531  
532  
533  
534  
535  
536  
537  
538  
539  
540  
541



542 Figure 3: maximum force of bioadhesion, F<sub>max</sub> (mN) of all the dressings prepared: a) without lyoprotectant,  
543 b) with glycerol and c) with mannitol as lyoprotectans (mean values±sd; n=6)

544  
545  
546  
547  
548  
549  
550  
551  
552  
553  
554  
555  
556  
557  
558  
559  
560  
561  
562  
563  
564

#### 3.1.4. Morphology

To understand if the system tridimensional networks could affect hydration and bioadhesion properties, morphology was assessed.







Figure 4 reports SEM images of transversal sections of CH 1, CH 1- HA and CH 1 – CS unloaded dressings and TA loaded dressings without lyoprotectans, and CH 1, CH 1- HA and CH 1 – CS dressings with glycerol and with mannitol.

CH 1 dressing showed a beehive structure with polyhedric cavities interconnected by pores having oval or round shapes. The cavities had dimensions of about 500  $\mu\text{m}$  while the pores ranged from 50 to 200  $\mu\text{m}$ . The presence of GAG did not change the system morphology while it markedly decreased the cavity dimensions that were around 200-300  $\mu\text{m}$  and furthermore the pore diameters that were of about 50  $\mu\text{m}$ . This difference in system porosity conceivably contributed to their hydration behavior. The TA loading did not modify the structure of the dressings.

The presence of glycerol as lyoprotectant did not substantially change dressing structure while the presence of mannitol caused a partially loss of polyhedric cavities and the structure resembled much more randomly organized sheets without marked modifications of the porosity. This modification could be responsible to the system behavior upon hydration and bioadhesion.

Since lyoprotectans did not markedly improve the technological properties of the dressings and considering mechanical, hydration and bioadhesive properties, lyoprotectant free systems prepared using chitosan at 1% w/w were considered for the further characterizations.



	CH 1	CH 1 - HA	CH1 - CS
No lyoprotectant	 <p>SEM HV: 8.0 kV    WD: 10.12 mm SEM MAG: 200 x    Det: SE BI: 10.00    Date(m/d/y): 11/07/17</p>	 <p>SEM HV: 8.0 kV    WD: 10.67 mm SEM MAG: 200 x    Det: SE BI: 10.00    Date(m/d/y): 11/07/17</p>	 <p>SEM HV: 8.0 kV    WD: 10.08 mm SEM MAG: 200 x    Det: SE BI: 10.00    Date(m/d/y): 11/07/17</p>
TA loaded dressing without lyoprotectant	 <p>SEM HV: 8.0 kV    WD: 9.96 mm SEM MAG: 200 x    Det: SE BI: 10.00    Date(m/d/y): 11/02/17</p>	 <p>SEM HV: 8.0 kV    WD: 9.36 mm SEM MAG: 200 x    Det: SE BI: 10.00    Date(m/d/y): 11/02/17</p>	 <p>SEM HV: 8.0 kV    WD: 9.36 mm SEM MAG: 199 x    Det: SE BI: 10.00    Date(m/d/y): 11/02/17</p>





Figure 4: SEM microphotographs of transversal sections of CH 1, CH 1- HA and CH 1 – CS unloaded dressings and TA loaded dressings without lyoprotectants, dressings with glycerol and with mannitol.

566  
567  
568  
569

570 3.1.4. FT-IR analysis

571 Figure 5 reports the FT-IR spectra of CH 1, CH 1 – HA and CH 1 – CS HA and CH+CS dressings and of CH  
572 powder (in the inset) as comparison.

573



574

575

576 Figure 5: FT-IR spectra of CH 1, CH 1 – HA and CH 1 – CS HA and CH+CS dressings. In the inset the FTIR  
577 spectrum of CH powder (free CH) is reported as comparison.

578

579 The three spectra shared many common features both in the number and position of the peaks and seemed  
580 to be dominated by the FT-IR pattern of CH (free CH as powder), where the region around 1630 and 1540  
581  $\text{cm}^{-1}$  is typical of the amide I and amide II stretching and bending modes (Radhakumary, Antony,  
582 Sreenivasan, 2011; Jayakumar, Prabhakaran, Nair, Tamura, 2010). Interestingly, the position of these peaks  
583 shifted to lower frequency with respect to free CH (i.e. not interacting with acetate ions) shown Figure 1 inset.  
584 In particular, the  $\text{-C=O}$  stretching of the amide I in free CH moved from 1652 to 1634  $\text{cm}^{-1}$  when it interacted  
585 with acetate ions and it remained in the same position even in the CH 1 - HA and CH 1 - CS systems.  
586 Moreover, a new peak around 1404  $\text{cm}^{-1}$  (correlated to the  $\text{-C-H-}$  bending) appeared in the spectra of CH 1  
587 dressing with respect to free CH and was found also in the spectra of CH 1 - HA and CH 1 - CS. The two  
588 mentioned spectral features have been correlated to charge-charge neutralization (salification) which most  
589 probably occurred between CH and acetate ions and dominated the spectra of all the three systems shown  
590 in Figure 1 (Shanti Krishna, Radhakumary, Sreenivasan, 2015).

591 This suggests that, in presence of acetate ions, the charge-charge interaction, involving chitosan amino  
592 groups, was preferentially between CH and acetate and therefore the further addition of HA and CS mostly  
593 interact with chitosan through less strong bonding such as polar interactions. Such results are in agreement  
594 with zeta potential values determined.


595

596 3.1.7. In vitro drug release properties

597 Figure 6 reports TA release profiles as function of time obtained for TA loaded dressings without  
598 lyoprotectans.

599 All the dressings were characterized by the same release behavior. TA is a water soluble drug (167 mg/ml)  
600 and considering the experimental conditions, the maximum concentration reached in the receiving phase  
601 was 1 mg/ml. In these conditions, TA release from all the dressings was relatively fast: the 50% of TA was  
602 released in about 30 min and reached quantitative and plateau value within about 3 h. This behavior should  
603 deliver TA at the application site, in the wounded bleeding lesion, to perform its procoagulant function as  
604 quickly as possible and moreover to sustain hemostatic activity for prolonged time to stabilize clot formation.

605  
606



607  
608

609 Figure 6: TA release profiles as function of time obtained for TA loaded dressings without lyoprotectans  
610 (mean values±sd; n=6).

611  
612

613 3.2. Sponge-like dressing biopharmaceutical properties

614 3.2.1. In vitro dynamic whole-blood clotting

615 Figure 7 shows % hemoglobin absorbance profiles as function of time evaluated for a) unloaded dressings  
616 and b) TA loaded formulations.

617 A higher degree of hemoglobin absorbance indicates a slower clot formation rate.

618 Whole blood clotting formation was relatively slow and the hemoglobin absorbance reached the minimum  
619 level after about 420 s. A faster clot formation occurred in presence of all the dressings and 30 s immediately  
620 after the contact between blood and formulations the % of free hemoglobin was around 20-50%. The  
621 minimum level of hemoglobin absorbance was reached after about 300 s. Chitosan capability to bind and  
622 aggregate platelets causing agglutination of erythrocytes and activation of hemostasis was predominant in all  
623 the formulation considered also in presence of GAG.

624 TA is a synthetic analogue of lysine and its antifibrinolytic activity is related to reversible bindings with four to  
625 five lysine receptor sites on plasminogen or plasmin: this prevents plasmin from binding to and degrading  
626 fibrin and preserves clot structure. TA showed a synergic activity with chitosan in enhancing clot formation:  
627 all the formulations reached the minimum in hemoglobin absorbance in about 180 s, presenting a better  
628 clotting performance with respect to unloaded dressings. TA CH 1 dressing allowed to maintain a % of  
629 hemoglobin at 420 s not significantly different from initial value, while CH 1 dressing determined a significant  
630 increase in % of hemoglobin comparing the initial value with respect to the final one (at 420 s). TA CH1 –HA  
631 and TA CH1- CS dressings proved to maintain clot integrity stable from the beginning up to 420 s, while the  
632 same compositions unloaded showed a partial clot modification at 90 s with a sharp increase in % of  
633 hemoglobin.

634 The presence of GAG slightly decreased the procoagulant activity of the dressings. In fact, HA and CS are  
635 reported in literature as anticoagulant materials. Fragments of HA having a molecular weight lower than 500  
636 kDa, as it is the case, cause clot structure susceptible to mechanical deformations and softening  
637 (Komorowicz, Balazs, Varga, Szabo, et al., 2016). CS is a sulfated glycosaminoglycan with heparin-like  
638 activity (Pandolfi, M., Hedner, U., 1984). On this basis, the procoagulant activity of the systems seems  
639 exclusively due to chitosan and its synergic effect with TA.

640

641

642

643

644

645

646

647

648

649

650

651

652

653

654  
655  
656  
657  
658  
659  
660  
661  
662  
663  
664  
665  
666  
667  
668  
669  
670  
671  
672  
673  
674  
675  
676  
677  
678  
679  
680  
681  
682  
683  
684  
685  
686  
687  
688  
689




Figure 7: % hemoglobin absorbance profiles as function of time evaluated for a) unloaded dressings and b) TA loaded formulations (mean values  $\pm$ sd; n=6).

690 3.2.2. In vitro and ex vivo biocompatibility and proliferation

691 Figure 8 reports % biocompatibility (a) and % of proliferation (b) of all unloaded or TA loaded dressings  
692 (polymeric mixtures used to prepare dressings) towards fibroblasts (NHDF) for 3 and 24 h of contact time,  
693 respectively, and the amounts of proliferating nuclei/area (c) (positively stained for BrdU) counted for all the  
694 unloaded and TA loaded dressings.

695 Independently of the concentrations considered, all the dressings were characterized by good  
696 biocompatibility properties towards fibroblasts also in presence of TA and the cell availability was not  
697 significantly different from those obtained with growth medium (GM, standard growth conditions).

698 Similarly, after 24 h the lower dressing concentrations determined the higher proliferation properties that  
699 becomes more evident in presence of tranexamic acid.

700 These results put in evidence that the presence of the hemostatic drug, TA, did not interfere with cell growth  
701 in the experimental conditions considered. **Similar results were observed by Cholewinski et al. (2009): carotid  
702 artery derived cells maintained their morphology with toxic reaction in presence of TA.**

703 Ex vivo skin cell proliferation (GM) was maximum in the first 24 h and decreased after 72 h and 7 days,  
704 **except for CS based system that had constant activity** (Figure 8 (c)). Unloaded dressings were able to  
705 sustain cell proliferation up to 7 days demonstrating a capability to enhance cell proliferation after tissue  
706 damage. **TA loaded dressings were characterized by the same proliferating properties as unloaded one,  
707 considering CH 1 and CH1 - HA dressings. As for CH1 - CS dressing the presence of TA significantly  
708 increased the system proliferation properties after 24 h and 7 days and allowed to obtain the better  
709 performance, with a prolonged effect up to one week. This probably was caused by the synergic effect of TA  
710 and CS on cell growth: CS was reported as able to enhance fibroblasts and endothelial cells proliferation  
711 (Sandri, Bonferoni, Rossi, Ferrari et al., 2015) while TA could stabilize fibrin clot without impairment of cell  
712 growth and proliferation (Cholewinski, Dietrich, Flanagan, Schmitz-Rode et al., 2009). At this purpose fibrin  
713 clot was conceivably formed just after skin biopsies and it could retain growth factors released by platelets  
714 during normal physiological process, on this perspective TA, as fibrinolytic drug, could preserve the clot  
715 integrity assisting cell proliferation (Wolberg and Campbell, 2008).**

716

717

718

719

720

721

722

723

724

725

726



727

728

729


730

731  
732  
733  
734  
735  
736  
737  
738  
739  
740  
741  
742  
743  
744  
745  
746  
747  
748  
749  
750  
751  
752  
753  
754  
755  
756  
757  
758  
759  
760  
761  
762  
763  
764  
765  
766  
767  
768  
769  
770  
771





772  
773  
774  
775  
776  
777  
778  
779  
780  
781  
782  
783  
784  
785  
786  
787  
788  
789  
790  
791  
792  
793  
794



795 Figure 8: % biocompatibility (a) and % proliferation (b) of all unloaded or TA loaded dressings (polymeric  
796 mixtures used to prepare dressings) towards fibroblasts (NHDF) for 3 and 24 h of contact time, respectively;  
797 amounts of proliferating nuclei (c) (positively stained for BrdU) for all the unloaded and TA loaded dressings  
798 after 24 and 72 h and 7 days of contact time (mean values  $\pm$  sd; n=8)  
799

800 4. Conclusions

801 Sponge-like dressings based on chitosan and chondroitin sulfate or hyaluronic acid were prepared by  
802 lyophilization and loaded with tranexamic acid. The presence of GAG conceivably caused the occurrence of  
803 either chitosan and hyaluronic acid or chitosan and chondroitin sulfate interactions. **The presence of  
804 glycosaminoglycans decreased hydration properties of the systems in a buffer simulating wound exudate –  
805 pH 7.2) and this was primarily due to dressing morphology. Chitosan based dressings had a beehive  
806 structure with polyhedric cavities of about 500  $\mu$ m, interconnected by pores having oval or round shapes (50  
807 to 200  $\mu$ m) while dressings based on chitosan in association with GAG markedly decreased the cavity  
808 dimensions (200-300  $\mu$ m) and with smaller pore diameters (about 50)  $\mu$ m. Liquid absorption is a key point in  
809 dressings to ensure hemostasis, to control wound bed hydration enhancing granulation phase and healing.  
810 **The presence of GAG in dressings significantly enhanced dressing bioadhesive properties considering as  
811 biological substrate egg-shell membrane to mimic wound bed. The association of chitosan with GAG allowed  
812 the consolidation of bioadhesive joint probably via hydrogen bonds that strengthen chitosan bioadhesion  
813 behavior, mainly due to charge-charge interaction between chitosan and the biological substrate. This is a****

814 functional property since bioadhesion is fundamental to favor an intimate and prolonged contact between  
815 wound dressings and lesion, avoiding formulation detachment and increasing hemostatic potential.  
816 TA release was fast to allow procoagulant function as quickly as possible and moreover to sustain  
817 hemostatic activity for prolonged time, to stabilize clot, moreover TA presented a synergic effect with  
818 chitosan to speed up clotting formation.

819 In vitro and ex vivo evaluations on fibroblasts and human skin, respectively, evidenced that the developed  
820 dressings enhanced cell proliferation.

821 **Bartley (2013) suggested that the association of chitosan with TA should improve hemostatic control and  
822 should lead to improved clinical outcomes in internal surgical wounds. In this paper, sponge-like dressings  
823 based on chitosan and GAG and loaded with TA demonstrated to combine both hemostasis and proliferation  
824 properties and it seemed promising in control bleeding and healing in wounds as well as in abdominal  
825 surgery.**

826

## 827 5. Acknowledgment

828 Dr. F Saporito wishes to thank ABOCA Società Agricola S.p.A. for her PhD grant. The authors wish to thank  
829 Prof. Boselli (Department of Drug Science, University of Pavia, I) for the rat blood collection, Prof. Nicoletti  
830 (Plastic and Reconstructive Surgery Unit, Department of Clinical Surgical Diagnostic and Pediatric Sciences,  
831 University of Pavia, Salvatore Maugeri Research and Care Institute, Pavia, Italy for the human skin biopsy  
832 and Dr. I. Tredici (Centro Arvedi, University of Pavia) for SEM measurements.

833

## 834 6. References

835 Ansari, T. M., Raza, A., Rehman, A. (2005). Spectrophotometric determination of Tranexamic acid in  
836 pharmaceutical bulk and dosage forms. *Analytical Sciences*, 21, 1133-1135.

837 **Bartley, J. (2013). Should chitosan and traxenamic acid be combined for improved hemostasis after sinus  
838 surgery? *Medical Hypothesis*, 81, 1036-1038.**

839 Bennet, B.L. (2017). Bleeding control using hemostatic dressings: lessons learned. *Wilderness and  
840 Environmental Medicine*, 28, S39-S49.

841 **Cataldo, F., Ursini, O., Lilla, E., Angelini, G. (2008). Radiation-induced crosslinking of collagen gelatin into a  
842 stable hydrogel. *J. Radioanal. Nucl. Chem.* 275, 125-131**

843 Champion, H. R., Bellamy, R. F., Roberts, C. P., Leppaniemi, A. (2003). A profile combat injury. *Journal of  
844 Trauma*, 54, S13-S19.

845 Chen, W. Y. J, Abatangelo, G. (1999). Functions of hyaluronan in wound repair. *Wound Repair and  
846 Regeneration*, 7, 79-89.

847 **Cholewinnski, E., Dietrich, M., Flanagan, T.C., Schmitz-Rode, T., Jockenhoevel, S. (2009). Traxenamic acid  
848 – an alternative to aprotinin in fibrin-based cardiovascular tissue engineering. *Tissue Engineering part A*. 15,  
849 3645-3653**

850 **Denunziere, A., Ferrier, D., and Domard, A. (1996). Chitosan-chondroitin sulfate and chitosan-hyaluronate  
851 polyelectrolyte complexes. Physico-chemical aspects. *Carbohydrate Polymers*. 29, 317-323**

852 Dunn, C. J., Goa, K. (1999). Tranexamic acid, a review of its use in surgery and other indications. *Drugs*, 57,  
853 1005-1032.

854 Feng, X., Leduc, M., Pelton, R. (2008). Polyelectrolyte complex characterization with isothermal titration  
855 calorimetry and colloid titration. *Colloids and Surfaces A: Physicochemical and Engineering Aspects*, 317,  
856 535–542.

857 Francesco, A., Tzanov, T. (2011). Chitin, chitosan and derivatives for wound healing and tissue engineering.  
858 *Advances in Biochemical Engineering/Biotechnology*, 125, 1–27.

859 Granville-Chapman, J., Jacobs, N., Midwinter, M. J. (2011). Pre-hospital haemostatic dressings: a systematic  
860 review. *Injury-International of the Care of the Injured*, 42, 447–59.

861 Hoemann, C.D., Sun, J., McKee, M. D., Chevrier, A., Rossomacha, E., Rivard, G. E., Hurtig, M., Buschmann  
862 M.D. (2007). Chitosan-glycerol phosphate/blood implants elicit hyaline cartilage repair integrated with porous  
863 subchondral bone in microdrilled rabbit defects. *Osteoarthritis Cartilage*, 15, 78-89.

864 Iliescu, M., Hoemann, C. D., Shive, M. S., Chenite, A., Buschmann, M.D. (2008). Ultrastructure of hybrid  
865 chitosan-glycerol phosphate blood clots by environmental scanning electron microscopy. *Microscopy  
866 Research Technique*, 71, :236-47.

867 Jayakumar, R., Prabhakaran, M., Nair, S.V., Tamura, H. (2010). Novel chitin and chitosan nanofibers in  
868 biomedical applications. *Biotechnology Advances*, 28, 142-150.

869 Jiang, D., Liang, J., Noble, P. W. (2007). Hyaluronan in tissue injury and repair, *Annual Review of Cell and  
870 Developmental Biology*, 23, 435-461.

871 Kabanov, V. A. (2005). Polyelectrolyte complexes in solution and in bulk. *Russian Chemical Reviews*, 74, 3–  
872 20.

873 Kabanov, V. A., Zezin, A. B. (1984). Soluble interpolymeric complexes as a new class of synthetic  
874 polyelectrolytes. *Pure Appl. Chem.*, 56, 343-354

875 Ker, K., Edwards, P., Rerei, P., Shakur, H., Roberts, I. (2012). Effect of tranexamic acid on surgical bleeding:  
876 systematic review and cumulative meta-analysis. *British Medical Journal*, 17, 344 e 3054.

877 Khoshmohabat, H., Paydar, S., Kazemi, H. M., Dalfardi, B. (2016). Overview of Agents Used for Emergency  
878 Hemostasis. *Trauma Monthly*. 21, e26023.

879 Komorowicz, E., Balazs, N., Varga, Z., Szabo, L., Bota, A., Kolev, K. (2017). Hyaluronic acid decreased the  
880 mechanical stability, but increases the lytic resistance of fibrin matrices, *Matrix Biol*. 63, 55-68

881 Le Cerf, D., Pepin, A. S., Niang, P.M., Cristea, M., Karakasyan-Dia, C., Picton, L. (2014). Formation of  
882 polyelectrolyte complexes with diethylaminoethyl dextran: Charge ratio and molar mass effect. *Carbohydrate  
883 Polymers* , 113, 217–224

884 Li, T.-T., Lou, C.-W., Chen, A.-P., Lee, M.-C., Ho, T.-F., Chen, Y.-S., Lin, J.-H. (2016). Highly absorbent  
885 antibacterial hemostatic dressing for healing severe hemorrhagic wounds, *Materials*, 9, 793.

886 Lynn, A. K., Yannas, L.V., Bonfield, W. (2004). Antigenicity and Immunogenicity of Collagen. *J. Biomed.  
887 Mater. Res. B Appl. Biomater.*, 71, 343-354

888 Marchand, C., Rivard, G. E., Sun, J., Hoemann, C.D. (2009). Solidification mechanisms of chitosan-glycerol  
889 phosphate/blood implant for articular cartilage repair. *Osteoarthritis Cartilage*, 17, 953-60.

890 Olsen, D., Yang, C., Bodo, M., Chang, R., Leigh, S., Baez, J., Carmichael, D., Perala, M., Hamalainen, E.R.,  
891 Jarvinen, M., Polarek, J. (2003). Recombinant collagen and gelatin for drug delivery. *Adv. Drug Deliv. Rev.*  
892 55, 1547-1567.

893 Ong, S.-Y., Wu, J., Mochhala, S. M., Tan, M.-H., Lu, J. (2008). Development of a chitosan-based wound  
894 dressing with improved hemostatic and antimicrobial properties. *Biomaterials*, 29, 4323.

895 Pandolfi, M., Hedner, U. (1984). The Effect of Sodium Hyaluronate and Sodium Chondroitin Sulfate on the  
896 Coagulation System In Vitro. *Ophthalmology*, 91, 864-866

897 Quan, K., Guofeng, L., Luana, D., Yuana, Q., Taob, L., Wanga, X. (2015). Black hemostatic sponge based  
898 on facile prepared cross-linked graphene. *Colloids and Surfaces B: Biointerfaces*, 132, 27-33.

899 Radhakumary, C., Antony, M., Sreenivasan, K. (2011). Drug loaded thermoresponsive and cytocompatible  
900 chitosan based hydrogel as a potential wound dressing. *Carbohydrate Polymers* 83, 705 – 713

901 Riva, F., Casasco, A., Nespoli, E., Icaro Cornaglia, A., Casasco, M., Faga, A., Scevola, S., Mazzini, G.,  
902 Calligaro, A. (2007). Generation of Human Epidermal Constructs on a Collagen Layer Alone, *Tissue*  
903 *Engineering*, 13, 2769-2779.

904 Rossi, S., Ferrari, F., Bonferoni, M.C., Caramella, C. (2001). Characterization of chitosan hydrochloride–  
905 mucin rheological interaction: influence of polymer concentration and polymer:mucin weight ratio, *European*  
906 *Journal of Pharmaceutical Sciences*, 12, 479–485

907 Rossi, S., Sandri, G., Ferrari, F., Bonferoni, M.C., Caramella, C. (2003a). Buccal delivery of acyclovir from  
908 films based on chitosan and polyacrylic acid, *Pharmaceutical Development and Technology*, 8, 199 – 208.

909 Rossi, S., Sandri, G., Ferrari, F., Bonferoni, M.C., Caramella, C. (2003b). Development of films and matrices  
910 based on chitosan and polyacrylic acid for vaginal delivery of acyclovir, *STP Pharma Sci.* 13, 181 - 190

911 Sabnis, S., Block L. H. (2000) Chitosan as an enabling excipient for drug delivery systems I. Molecular  
912 modifications. *International Journal of Biological Macromolecules*, 27, 181 – 186

913 Sandri, G., Aguzzi, C., Rossi, S., Bonferoni, M.C., Bruni, G., Boselli, C., Cornaglia, A.I., Riva, F., Viseras, C.,  
914 Caramella, C., Ferrari, F. (2017). Halloysite and chitosan oligosaccharide nanocomposite for wound healing,  
915 *Acta Biomaterialia*, 57, 2016-224.

916 Sandri, G., Bonferoni, M. C., D'Autilia, F., Rossi, S., Ferrari, F., Grisoli, P., Sorrenti, M., Catenacci, L., Del  
917 Fante, C., Perotti, C., Caramella, C. (2013). Wound dressings based on silver sulfadiazine SLN for tissue  
918 repairing, *European Journal of Pharmaceutics and Biopharmaceutics*, 84, 84-90

919 Sandri, G., Bonferoni, M.C, Rossi, S., Ferrari, F., Mori, M., Del Fante, C., Perotti, C., Scudeller, L.,  
920 Caramella, C., (2011). Platelet lysate formulations based on mucoadhesive polymers for the treatment of  
921 corneal lesions. *Journal of Pharmacy and Pharmacology*, 63, 189–219.

922 Sandri, G., Bonferoni, M.C., Rossi, S., Ferrari, F., Mori, M., Cervio, M., Riva, F., Liakos, I., Athanassiou, A.,  
923 Saporito, F., Marini, L., Caramella C. (2015) Platelet lysate embedded scaffolds for skin regeneration. *Expert*  
924 *Opin. Drug Del.* 12, 525-54

925 Sandri, G., Rossi, S., Bonferoni, M. C., Ferrari, F., Mori, M., Caramella, C. (2012) The role of chitosan as a  
926 mucoadhesive agent in mucosal drug delivery. *Journal of Drug Delivery Science and Technology*, 21, 275-  
927 284

928 Schatz, C., Domard, A., Viton, C., Pichot, C., Delair, T. (2004). Versatile and Efficient Formation of Colloids  
929 of Biopolymer-Based Polyelectrolyte Complexes. *Biomacromolecules*, 5, 1882-1892

930 Seon, G. M., Lee, M. H., Kwon, B.-J., Kim, M. S., Koo, M.-A., Kim, D., Seomun, Y., Kim, J.-T., Park, J.-C.-  
931 (2017). Functional improvement of hemostatic dressing by addition of recombinant baxotropin, *Acta*  
932 *Biomaterialia*, 48, 175-185.

933 Shanti Krishna, A., Radhakumary, C., Sreenivasan, K. (2015). Calcium ion modulates protein release from  
934 chitosan-hyaluronic acid poly electrolyte gel. *Polymer Engineering and Science*. 55, 2089-2097 (2007).  
935 *Journal of Materials Science: Materials in Medicine* 42, 1719.

936 Shields, D. W., Crowley, T. P. (2014). Current concepts, which effect outcome following major hemorrhage.  
937 *Journal of emergencies trauma and shock*, 7, 20-24.

938 Silbert, J. E., Sugumaran, G. (2002). Biosynthesis of chondroitin/dermatan sulfate, *Iubmb Life*, 54, 177-186,  
939 Sudheesh Kumar, P. T., Lakshmanan, V. K., Anilkumar, T. V., Ramya, C., Reshmi, P., Unnikrishnan, A. G.,  
940 Nair, S. V, Jayakumar, R. (2012). Flexible and Microporous Chitosan Hydrogel/Nano ZnO Composite  
941 Bandages for Wound Dressing: In Vitro and In Vivo Evaluation. *ACS Applied Materials & Interfaces*, 4, 2618-  
942 2629.

943 Szucs, M., Sandri, G., Bonferoni, M. C., Caramella, C., Vaghi, P., Szabó-Révész, P., Eros, I. (2008).  
944 Mucoadhesive behaviour of emulsion containing polymeric emulsifier. *European. Journal of Pharmaceutical*  
945 *Sciences*, 34, 226–235.



946 Tao, Y, Lu, Y., Sun, Y., Gu, B, Lu, W., Pan, J. (2009). Development of mucoadhesive microspheres of  
947 acyclovir with enhanced bioavailability. *International Journal of Pharmaceutics*, 378, 30–36.

948 [Wolberg, A.S., Campbell, R.A. \(2008\). Thrombin generation, fibrin clot formation and hemostasis,](#)  
949 [Transfusion and Apheresis Science](#), 38, 15–23

950 Yamada, S., Sugahara, K. (2008). Potential therapeutic application of chondroitin sulfate/dermatan sulfate,  
951 *Current Drug Discovery. Technologies*, 5, 289-301.

952

# Chitosan-glycosaminoglycan based sponge like dressings loaded with tranexamic acid (TA)




chitosan

chitosan  
hyaluronic acid

chitosan  
chondroitin sulfate

## ex vivo proliferation on human skin



## In vitro whole blood clotting

